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A B S T R A C T
Background
The estimated likelihood of lower limb amputation is 10 to 30 times higher amongst people with diabetes compared to those without
diabetes. Of all non-traumatic amputations in people with diabetes, 85% are preceded by a foot ulcer. Foot ulceration associated
with diabetes (diabetic foot ulcers) is caused by the interplay of several factors, most notably diabetic peripheral neuropathy (DPN),
peripheral arterial disease (PAD) and changes in foot structure. These factors have been linked to chronic hyperglycaemia (high levels
of glucose in the blood) and the altered metabolic state of diabetes. Control of hyperglycaemia may be important in the healing of
ulcers.
Objectives
To assess the effects of intensive glycaemic control compared to conventional control on the outcome of foot ulcers in people with type
1 and type 2 diabetes.
Search methods
In December 2015 we searched: The Cochrane Wounds Specialised Register; The Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library); Ovid MEDLINE; Ovid MEDLINE (In-Process & Other Non-Indexed Citations); Ovid EM-
BASE; EBSCOCINAHL; Elsevier SCOPUS; ISI Web of Knowledge Web of Science; BioMed Central and LILACS. We also searched
clinical trial databases, pharmaceutical trial databases and current international and national clinical guidelines on diabetes foot man-
agement for relevant published, non-published, ongoing and terminated clinical trials. There were no restrictions based on language
or date of publication or study setting.
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Selection criteria
Published, unpublished and ongoing randomised controlled trials (RCTs) were considered for inclusion where they investigated the
effects of intensive glycaemic control on the outcome of active foot ulcers in peoplewith diabetes.Non randomised and quasi-randomised
trials were excluded. In order to be included the trial had to have: 1) attempted to maintain or control blood glucose levels and measured
changes in markers of glycaemic control (HbA1c or fasting, random, mean, home capillary or urine glucose), and 2) documented the
effect of these interventions on active foot ulcer outcomes. Glycaemic interventions included subcutaneous insulin administration,
continuous insulin infusion, oral anti-diabetes agents, lifestyle interventions or a combination of these interventions. The definition of
the interventional (intensive) group was that it should have a lower glycaemic target than the comparison (conventional) group.
Data collection and analysis
All review authors independently evaluated the papers identified by the search strategy against the inclusion criteria. Two review authors
then independently reviewed all potential full-text articles and trials registry results for inclusion.
Main results
We only identified one trial that met the inclusion criteria but this trial did not have any results so we could not perform the planned
subgroup and sensitivity analyses in the absence of data. Two ongoing trials were identified which may provide data for analyses in a
later version of this review. The completion date of these trials is currently unknown.
Authors’ conclusions
The current review failed to find any completed randomised clinical trials with results. Therefore we are unable to conclude whether
intensive glycaemic control when compared to conventional glycaemic control has a positive or detrimental effect on the treatment of
foot ulcers in people with diabetes. Previous evidence has however highlighted a reduction in risk of limb amputation (from various
causes) in people with type 2 diabetes with intensive glycaemic control. Whether this applies to people with foot ulcers in particular
is unknown. The exact role that intensive glycaemic control has in treating foot ulcers in multidisciplinary care (alongside other
interventions targeted at treating foot ulcers) requires further investigation.
P L A I N L A N G U A G E S U M M A R Y
Controlling blood glucose in treating diabetic foot ulcers (sores)
Background: People with diabetes can develop foot ulcers (sores) for a number of reasons. This includes nerve damage and reduced
blood flow to the feet and legs. Having high blood glucose may affect the ability of foot ulcers to heal and therefore intensively
controlling blood glucose may be beneficial.
Review question: This Cochrane review aimed to answer the question; how does controlling blood glucose more intensively compared
to conventional blood glucose control influence foot ulcer healing in people with diabetes?
What we found: We did not find any trials which have been completed on this topic with available results. The only trial which met
our criteria for inclusion had been terminated due to encountering difficulties with recruiting participants. Therefore we cannot be
sure whether controlling blood glucose intensively when people have diabetic foot ulcers is beneficial or harmful. The lack of evidence
however should not deter efforts to achieve optimal glycaemic control in people with diabetic foot ulcers to encourage healing as is
current practice. We believe there are currently two trials underway which may provide some evidence on this topic once completed.
This Plain Language Summary is up to date as of 7 December 2015.
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B A C K G R O U N D
Description of the condition
In 2011, 366 million people worldwide (8.3% of adults) were es-
timated to have diabetes mellitus (IDF 2012). It is expected that
this figure will reach 552 million (10% of adults) by 2030 (IDF
2012). Diabetes mellitus is a metabolic disorder characterised by
dysregulation of blood glucose levels. Type 1 diabetes (previously
known as insulin-dependent, juvenile or childhood-onset) is char-
acterised by deficient insulin production and requires daily ad-
ministration of insulin (IDF 2012). The cause of type 1 diabetes
is not known and it is currently not preventable (IDF 2012). Type
2 diabetes (formerly known as non-insulin-dependent or adult-
onset) results from the body’s ineffective use of insulin. Ninety per
cent of people with diabetes, worldwide, have type 2 diabetes (IDF
2012). One of the major complications of diabetes is diabetic foot
ulceration (Boulton 2004). A diabetic foot ulcer (an ulcer which
occurs due to diabetes) has been defined as either a full-thick-
ness wound below the ankle in people with diabetes, irrespective
of duration (Apelqvist 1999), or a lesion of the foot penetrating
through the dermis (Schaper 2004). The prevalence of foot ulcer-
ation in people diagnosed with diabetes is 4% to 10%; the annual
population incidence is 1% to 4%, and the lifetime incidence is
as high as 25% (Singh 2005). In a recent multi-centre study, poor
glycaemic (blood glucose) control was evident in nearly half of
the participants who had foot ulcers, with 49% having an HbA1c
(glycaemic measure) level above 8.4% (Schaper 2012).
Foot ulceration is caused by the interplay of several factors, most
notably diabetic peripheral neuropathy (DPN, i.e. loss of sensation
to the foot), peripheral arterial disease (PAD, i.e. lack of blood-
flow) and changes in foot structure (Clayton 2009; Shenoy 2012).
These factors have been linked to chronic hyperglycaemia and
the altered metabolic state associated with diabetes (Ikem 2010;
Ogbera 2008; Tesfaye 2012).The prevalence of DPN ranges from
16% to 66% in people with diabetes (Cook 2012). The prevalence
rates of PAD are as high as 50% in people with diabetic foot ulcers
(Hinchliffe 2012). What is most notable is that within one year of
an ulcer healing, up to 60% of patients will develop another foot
ulcer (Wu 2007), and often the end point is lower limb amputa-
tion.
It is currently estimated that there is an amputation every 30 sec-
onds, somewhere in the world that is due to diabetes (Game 2012).
The estimated likelihood of amputation is 10 to 30 times higher
amongst people with diabetes compared to those without diabetes
and 85% of all amputations in people with diabetes are preceded
by a foot ulcer (Boulton 2004; Singh 2005). The five-year mortal-
ity rate after the onset of a foot ulcer ranges from 43% to 55%, and
is up to 74% for patients with lower limb amputation (Robbins
2008).
Description of the intervention
Chronic hyperglycaemia appears to be one of the most impor-
tant factors in the development and healing of diabetic foot ulcers
(Christman 2011; Falanga 2005). Current guidelines recommend
that treatment of diabetic foot ulcers should involve a multidis-
ciplinary team, as well as utilising several interventions (Table 1).
This review was performed to clarify the effect of intensive gly-
caemic control on the healing of foot ulcers in people with dia-
betes.
The management of diabetes includes glycaemic control (Table
2) (Daroux 2010; Geraldes 2010; Giacco 2010; Inzucchi 2012).
A common list of glycaemic control medications used in diabetes
management is shown in Table 3. Most guidelines recommend
a glycaemic control target of 7% or lower for HbA1c (glycated
haemoglobin) (Table 2). The revised guidelines of the American
Diabetes Association (ADA) and the European Association for
the Study of Diabetes (EASD) recommend individualisation, with
more stringent (6.5% or lower) or less stringent (8% or lower)
HbA1c targets as appropriate for individuals (ADA 2012; Cheung
2009; Inzucchi 2012). There is marked variation in the defini-
tion of intensive glycaemic control between guidelines and trials
(Hemmingsen 2011a). For the purposes of this review we included
trials where an intervention has been performed with the aim of
achieving improved glycaemic control in comparison to a conven-
tional control group.
Most of the current glycaemic targets for diabetes are based on
several landmark trials that investigated the effects of intensive
glycaemic control compared to conventional treatments (Table 2)
(Cheung 2009; Hemmingsen 2011b; Macisaac 2011; Mazzone
2010). The findings from these studies also illustrate the benefits
and risks associated with intensive glycaemic control. Therefore,
when investigating intensive glycaemic control as a potential in-
tervention for diabetic foot ulcers, it is important to take into ac-
count the present literature underpinning current glycaemic man-
agement.
Intensive glycaemic control implemented in the Diabetes Con-
trol and Complications Trial (DCCT) and the United Kingdom
Prospective Diabetes Study (UKPDS) led to a reduction in the
progression and development of microvascular (small vessel) com-
plications including DPN (Mattila 2010). The UKPDS demon-
strated a 37% reduction in the risk of microvascular complications
for each 1% decrease in HbA1c (95% confidence interval: 33% to
41%) (UKPDS 1998; Stratton 2000). Similarly, the ADVANCE
trial found a 14% relative risk reduction for major microvascu-
lar events in the intensive control group when compared to the
standard control group (9.4% versus 10.9%; hazard ratio (HR)
0.86; 95% CI: 0.77 to 0.97), although mainly in terms of reduced
incidence of nephropathy (kidney disease) (ADVANCE 2008).
A recent Cochrane review concluded that intensive glucose con-
trol reduced the risk of amputation by 36% in type 2 diabetes (rel-
ative risk (RR) 0.64, 95% CI: 0.43 to 0.95; 6960 participants in
eight trials) (Hemmingsen 2011b). In addition there was an 11%
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relative risk reduction (RR 0.89, 95% CI: 0.83 to 0.95; 25,760
participants in four trials) and a 1% to 2% absolute risk reduc-
tion in composite microvascular outcomes in favour of intensive
glycaemic control for all included trials (Hemmingsen 2011b). A
number of meta-analyses have demonstrated that the incidence
of hypoglycaemia (low blood glucose) was increased during in-
tensive glycaemic control, making this a significant adverse out-
come (Hemmingsen 2011b; Ma 2009; Mattila 2010). It must be
noted that the beneficial effects on microvascular complications
from using intensive glycaemic control took more than five years
to emerge, and the benefits were less pronounced for people with
advanced type 2 diabetes compared to those with new-onset type
2 diabetes (Hemmingsen 2011b;Mattila 2010). Despite this, data
on retinopathy (disease of the retina) suggest that people with the
advanced stages of type 2 diabetes may also benefit from intensive
glycaemic control (Hemmingsen 2011a). The effects of intensive
glycaemic control in people with type 1 diabetes demonstrated in
the DCCT were still evident after 14 years of follow-up (i.e. long
after the intervention was completed), and that phenomenon had
been termed ’glycaemicmemory’ (Giacco 2010).More recent data
suggested that glycaemic memory also occurred in people with
type 2 diabetes, where it is termed the ’legacy effect’, whereby the
benefits of earlier interventions were still evident later on in the
disease course (Giacco 2010).
While intensive therapy, with the goal of achieving near normal
HbA1c levels (7%), has altered the clinical course of nephropathy,
neuropathy and retinopathy, the majority of studies have not ex-
amined the benefits of intensive therapy when implemented after
the onset of late diabetes complications, such as diabetic foot ul-
cers (Nathan 2012).
How the intervention might work
Optimum healing of a foot ulcer requires a well-orchestrated in-
tegration of molecular and biological events including cell mi-
gration, proliferation, extracellular matrix deposition and remod-
elling, which is hindered by the effects of hyperglycaemia (Falanga
2005; Rafehi 2010). Hyperglycaemia has been associated with de-
layed healing of foot ulcers (Burakowska 2006; Christman 2011;
D’Souza 2009; Falanga 2005; Rafehi 2010). Interventions that
target improvements in glycaemic control are thus of potential
benefit. Delayed healing of foot ulcers appears to be the net re-
sult of both microvascular and macrovascular disease (Burakowska
2006; Dinh 2005). Well-orchestrated wound healing is essential
for tissue replacement and restoration, and generally involves three
main phases: acute inflammation, proliferation, and remodelling
(Rafehi 2010). In contrast, diabetic foot ulcers do not follow the
orderly process of wound healing and differ at a molecular level
in terms of expression of growth factors, cytokines and proteins
(Dinh 2005; Rafehi 2010). These processes are known to be af-
fected by hyperglycaemia.
Several proposed pathogenic pathways exist to explain the adverse
effects of hyperglycaemia (Geraldes 2010). These include: 1) ac-
tivation of the polyol pathway; 2) non-enzymatic glycosylation
and formation of advanced glycation end products (AGEs); 3)
activation of the diacylglycerol- (DAG) protein kinase C path-
way; and 4) overactivity of the hexosamine pathway (Brownlee
2004; Geraldes 2010; Giacco 2010; Gupta 2010). All four mecha-
nisms have been linked to a single, unified preceding event, namely
mitochondrial overproduction of reactive oxygen species (ROS)
(Brownlee 2004). ROS are known to promote cellular dysfunction
through damage to DNA synthesis, oxidation of lipids and amino
acids and inactivation of key enzymes involved in metabolic func-
tion, which are implicated in the formation of diabetic foot ulcers.
Hyperglycaemia also promotes endothelial dysfunction, vascular
leakage and impaired angiogenesis (formation of new blood ves-
sels) originating from the above mentioned pathways, and leads to
activation of the inflammatory response via activation of nuclear
factor kappa-light-chain-enhancer of activated B cells (NF-κB)
(D’Souza 2009; Giacco 2010). The incidence of infection is also
increased inpeoplewith diabetes and immunological disturbances,
such as deficiencies in polymorphonuclear leukocyte, monocyte
and macrophage (types of white blood cell) function have been
noted during hyperglycaemia (Delamaire 1997; Stegenga 2008).
All these factors, which are a consequence of hyperglycaemia, may
play a role in delayed healing of foot ulcers.
A recent observational study showed that HbA1c was an impor-
tant clinical predictor of the rate of wound healing; with each 1%
increase in HbA1c level associated with a decrease in the wound
healing rate of 0.028 cm² per day (95% CI: 0.003 to 0.054)
(Christman 2011). Despite this, the effects of short-term reduc-
tion in HbA1c did not appear to have any effect on endothelial
function in patients with type 2 diabetes with a history of poor gly-
caemic control (Bagg 2001). Therefore, there remains a clear need
to document benefits associated with improved glycaemic control
in people with diabetic foot ulcers. While chronic complications
of diabetes such asDPN and PADmaybe difficult to reverse, it can
be postulated that aspects of ulcer healing relating to immunolog-
ical and connective tissue function may be more amenable to im-
provement if normoglycaemia (normal level of glucose in blood)
is achieved (Jeffcoate 2004).
Why it is important to do this review
Foot ulcers continue to be a significant burden for people with di-
abetes, their caregivers and the healthcare system (Schaper 2012).
The outcome of a foot ulcer in people with diabetes should not
only be viewed from a clinical perspective (e.g. healing or amputa-
tion), but also from an individual and socioeconomic perspective.
Health-related quality of life (HRQoL) is significantly reduced
in people with diabetes, and further impaired by the presence of
foot disease, whilst it is improved with foot ulcer healing (Hogg
2012). Healthcare costs associated with foot ulcers and amputa-
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tions contribute significantly to the financial burden of diabetes
(Jones 2008). In the United States in 2008, the total number of
discharges attributed to diabetes-related amputations was 45,000.
The average length of stay was 10.1 days and the in-hospital mor-
tality proportion was 1.29% (Cook 2012). The mean hospital
charges were USD 56,216 per patient and the estimated aggregate
cost for the year 2008 was USD 2,548,319,965 (Cook 2012).
Therefore, foot ulceration in people with diabetes has substantial
socioeconomic, quality-of-life, and healthcare implications, and
it is imperative that all efforts be made to prevent and treat the
burden of foot ulceration in order to reduce amputation rates - as
highlighted by the St Vincent Declaration in 1989 (Game 2012).
Advances in the treatment of diabetic foot ulcers are promising,
however the intrinsic pathophysiological abnormalities of hyper-
glycaemia that lead to ulceration and delayed ulcer healing cannot
be ignored (Falanga 2005).
O B J E C T I V E S
To assess the effects of intensive glycaemic control compared with
conventional control on the outcome of foot ulcers in people with
type 1 and type 2 diabetes.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered randomised controlled trials (RCTs) for inclusion
where they investigated the effects of intensive glycaemic control
on the outcome of active foot ulcers in people with diabetes. We
excluded non-randomised and quasi-experimental trials.
Types of participants
Men and women (over 18 years) diagnosed with type 1 or type
2 diabetes by clearly-defined, accepted standards relevant to the
time of the study, with an active foot ulcer that had any of the
following aetiologies (causes):
• neuropathic, or
• neuro-ischaemic, or
• ischaemic, with or without
• infection (as clinically or diagnostically documented by
laboratory analysis).
For the purposes of this review, venous ulcers, malignant ulcers
and post-surgical ulcers were excluded.
Types of interventions
Weplanned to include trials that had assessed any intervention that
aimed to achieve a lower glycaemic target in a diabetes group (i.e.
near normal glycaemic levels) when compared to a control group
with a higher glycaemic target. The latter group was defined as the
’conventional’ group. Therefore the intensive group would have
had a lower glycaemic target level compared to the conventional
group in the trial.
Therefore, we sought to include any intervention that had:
• attempted to maintain or control blood glucose levels and
measured changes in markers of glycaemic control (HbA1c or
fasting, random, mean plasma glucose, home capillary or urine
glucose), and
• documented the effect of these interventions on active foot
ulcer outcomes.
Allowable interventions included subcutaneous insulin adminis-
tration, continuous subcutaneous insulin infusion using an insulin
pump or oral anti-diabetes agents or a combination of both, or
any lifestyle interventions or both (Table 4). The overall definition
of the interventional (intensive) group was that it should have a
lower glycaemic target than the comparison (conventional) group.
Pharmaceutical treatments included any route of administration,
dose, duration or frequency of insulin or other pharmaceutical
agents, or both.
Types of outcome measures
Primary outcomes
• Number of ulcers healed.
• Time to complete ulcer healing.
• Change in ulcer severity reported as a change in an ulcer
grading score using a well-defined validated ulcer grading scale
e.g. University of Texas Wound Classification System (UTWCS)
that measures the depth, presence of infection and ischemia of an
ulcer (Armstrong 1998).
• Incidence of amputation related to foot ulcers (identified
on International Classification of Disease (ICD) codes (NCCH
2006).
Secondary outcomes
• New ulcer development (recurrence of an ulcer or initiation
of a new ulcer).
• Proportion of infected ulcers at study completion.
• Adverse events: adverse events were to be noted from each
individual trial, and, where trial reports were based on a sound
methodology with standardised approach to detect and assess
adverse events, these were to be included in any potential analysis
and judged on a case-by-case basis. Treatment-focused examples
included: adverse drug reaction requiring hospitalisation; weight
gain; and hypoglycaemia. Disease-focused examples included:
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worsening of neuropathy (clinically or using a validated
neuropathy score); development or worsening of PAD (clinically
or by diagnostic measurement such as ankle brachial index
(ABI); gangrene; congestive heart failure; chronic kidney disease
(CKD) (stages 1-5); dialysis; retinopathy and documented
diabetic ketoacidosis (DKA); hyperosmolar hyperglycaemic state,
hyperglycaemia; and lactic acidosis.
• Effect on HRQoL: As measured by a validated quality of
life (QOL) measurement tool that is disease-specific to foot
ulcers or generic to QOL or both.
• Cost of intervention compared to conventional treatment,
including: direct medical costs; direct non-medical costs (e.g.
transport, assistive devices); indirect costs (e.g. sick leave,
reduced productivity, early retirement and premature death);
disability-adjusted life years (DALY); and years of life lost (YLL).
• All-cause mortality.
Search methods for identification of studies
Electronic searches
We searched the following electronic databases to identify reports
of relevant randomised clinical trials:
• The Cochrane Wounds Specialised Register; (searched 7
December 2015);
• The Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library 2015, Issue 11);
• Ovid MEDLINE (1946 to 7 December 2015);
• Ovid MEDLINE (In-Process & Other Non-Indexed
Citations) (searched 7 December 2015);
• Ovid EMBASE (1974 to 7 December 2015);
• EBSCO CINAHL Plus (1937 to 7 December 2015);
• Elsevier SCOPUS (1960 to 13 December 2015);
• ISI Web of Knowledge Web of Science (1965 to 13
December 2015);
• BioMed Central (1997 to 13 December 2015);
• LILACS (1995 to 13 December 2015).
We used the following search strategy in The Cochrane Central
Register of Controlled Trials (CENTRAL):
#1 MeSH descriptor: [Blood Glucose] explode all trees
#2 MeSH descriptor: [Hypoglycemic Agents] explode all trees
#3 MeSH descriptor: [Hyperglycemia] explode all trees
#4 MeSH descriptor: [Hypoglycemia] explode all trees
#5 MeSH descriptor: [Insulin] explode all trees
#6 MeSH descriptor: [Metformin] explode all trees
#7 MeSH descriptor: [Thiazolidinediones] explode all trees
#8 MeSH descriptor: [alpha-Glucosidases] explode all trees
#9 MeSH descriptor: [Glucagon-Like Peptide 1] explode all trees
#10 MeSH descriptor: [Acarbose] explode all trees
#11 (blood glucose):ti,ab,kw
#12 (((glycaemic or glycemic) next control) or “intensive glucose
control”):ti,ab,kw
#13 ((hypoglycaemi* or hypoglycemi*) next (agent* or drug*)):
ti,ab,kw
#14 (oral next (hypoglycaemi* or hypoglycemi*)):ti,ab,kw
#15 (“fasting glucose” or “glucose target”):ti,ab,kw
#16 ((anti-diabetes next medication*) or (diabetes next medica-
tion*) or insulin* or sulphonyureas or metformin or thiazolidine-
dione* or DPP-4 inhibitor* or glitinide or (glucosidase next in-
hibitor*) or biguinide or “GLP-1 agonist” or acarbose or (incretin
next enhancer*) or (incretin next mimetic*) or HbA1c):ti,ab,kw
#17 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or
#11 or #13 or #14 or #15 or #16
#18 MeSH descriptor: [Foot Ulcer] explode all trees
#19 MeSH descriptor: [Diabetic Foot] explode all trees
#20 (diabet* near/3 ulcer*):ti,ab,kw
#21 (diabet* near/3 (foot or feet)):ti,ab,kw
#22 (diabet* near/3 wound*):ti,ab,kw
#23 (diabet* near/3 defect*):ti,ab,kw
#24 (“foot gangrene” or amputat*):ti,ab,kw
#25 #18 or #19 or #20 or #21 or #22 or #23 or #24
#26 #17 and #25
The search strategies were adapted for Ovid MEDLINE, Ovid
EMBASE, EBSCOCINAHLand canbe found inAppendix 2.We
combined the Ovid MEDLINE search with the Cochrane Highly
Sensitive Search Strategy for identifying randomised trials in
MEDLINE: sensitivity- and precision-maximising version (2008
revision) (Lefebvre 2011).We combined the EMBASE searchwith
the Ovid EMBASE filter developed by the UK Cochrane Centre
(Lefebvre 2011). We combined the CINAHL searches with the
trial filters developed by the Scottish Intercollegiate Guidelines
Network (SIGN) (SIGN 2012). We did not restrict studies with
respect to language, date of publication or study setting.
Searches of the Cochrane Wounds Specialised Register, CEN-
TRAL, MEDLINE, EMBASE and CINAHL were carried out at
Cochrane Wounds editorial base. We modified the original search
strategy shown above to search the SCOPUS, Biomed Central,
Web of Science and LILACS databases.
We also searched the following ongoing trial databases for relevant
published, non-published, ongoing and terminated clinical trials:
• EU Clinical Trials Register (https://
www.clinicaltrialsregister.eu/index.html) (last searched 7
December 2015);
• ClinicalTrials.gov (http://www.clinicaltrials.gov/); (last
searched 7 December 2015);
• WHO International Clinical Trials Registry Platform
(ICTRP) (http://www.who.int/ictrp/en/) (last searched 7
December 2015);
• Current Controlled Trials (http://www.controlled-
trials.com) (last searched 7 December 2015).
We searched the pharmaceutical trials databases listed below
(known pharmaceutical companies involved in manufacturer of
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diabetes medication) for relevant published, non-published, on-
going and terminated clinical trials:
• AstraZeneca Clinical Trials web site (
www.astrazenecaclinicaltrials.com) (last searched 7 December
2015);
• Eli Lilly and Company Clinical Trial Registry (
www.lillytrials.com) (last searched 7 December 2015);
• Novartis (https://www.novartisclinicaltrials.com/
TrialConnectWeb/home.nov) (last searched 7 December 2015);
• Novo Nordisk (http://www.novonordisk-trials.com/
WebSite/Search/Default.aspx) (last searched 7 December 2015);
• MSD (http://www.msd-australia.com.au/research/
discoveryanddevelopment/pages/clinicaldevelopment/l) (last
searched 7 December 2015);
• Servier (http://www.servier.co.uk/content/clinical-trials)
(last searched 7 December 2015).
For completeness, we searched through any clinical guidelines pro-
duced by the Joanna Briggs Institute, the National Institute for
Health and Care Excellence (NICE), the National Health Ser-
vice (NHS), the National Health and Medical Research Coun-
cil (NHMRC) Australia, the Scottish Intercollegiate Guidelines
Network (SIGN), National Clearinghouse and the International
Working Group on the Diabetic Foot for any studies or publi-
cations of relevance that had not been identified through other
search options.
Where translation(s) were required, we contacted the original
trial authors first to acquire an English language version of the
manuscript. If the authors were not able to provide an English ver-
sion, or where we did not receive any correspondence back from
the authors, the articleswere translated toEnglish using translation
services from our institution and then the authors were contacted
again to clarify our understanding of the study. If the authors were
unable to clarify the data, we planned to still attempt to use the
trial.
Searching other resources
We checked the reference lists of all full-text articles considered
for inclusion for any further studies of relevance.We contacted
key local and international pharmaceutical groups regarding any
unpublished trials. We also contacted several leading academics,
clinicians and researchers in the area of diabetes management for
information about any prospective or past studies not identified
by the literature searches.
Data collection and analysis
Selection of studies
All review authors participated in the title and abstract screening of
the search results. Two review authors (MF and RS) retrieved and
assessed articles for inclusion independently using the following
selection criteria. Included studies needed to:
• investigate changes in the glycaemic state of participants
with type 1 or type 2 diabetes via changes in markers of
glycaemic control (HbA1c or fasting, random, mean plasma
glucose, home capillary or urine glucose), and
• report foot ulcer outcomes.
We obtained full-text publications of all articles meeting these se-
lection criteria, or abstracts where these criteria could not be de-
termined, and excluded any articles that we deemed not to be suit-
able (exclusion after screening of full text). Three third parties (JG,
KS, YT) resolved any differences in opinion regarding whether to
include or exclude a study. If no resolution was achieved, we con-
tacted the original authors of the study for further clarification.We
held teammeetings when there was a need to make a final decision
on inclusion. The PRISMA flow diagram in Figure 1 shows the
study selection process (Moher 2009), and the Excluded studies
table shows the reasons for exclusion for all the excluded trials.
All citations were managed using Endnote version 5.1 (Endnote
2012).
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Figure 1. Flow diagram.
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Data extraction and management
Two review authors (MF and RS) would have independently ex-
tracted data, with a third and fourth review author (MC and PB)
resolving any disagreements.We planned to enter data into a struc-
tured electronic data format, using the Cochrane Wounds extrac-
tion form to collect and organise data.This included information
concerning:
• general information about the study (i.e. location, setting,
aims);
• study eligibility;
• characteristics of study methods;
• participants;
• intervention groups;
• outcomes;
• ’risk of bias’ assessment;
• subgroup analyses
The data to be extracted also included information on participant
characteristics, study design, interventions utilised, outcomes as-
sessed, and adverse events. MF and RS independently extracted
all ongoing trial information and reported and compared it in ap-
propriate Tables.
Dealing with duplicate publications
When more than one publication was found for a study, we evalu-
ated all publications together to extract the maximum amount of
relevant information. We resolved any discrepancies between the
studies by contacting the study authors. If there were repeated ob-
servations of the same participants, we planned to use the longest
follow-up period for defining outcome measures of the study.
Assessment of risk of bias in included studies
We planned to assess risk of bias using the guidelines provided
in the Cochrane Handbook of Systematic Reviews of Interventions
(Higgins 2011a). We would have rated risk of bias as low, high
or unclear in nature (Higgins 2011a), and planned to include a
’risk of bias’ graph and ’risk of bias’ summary. Two review authors
(MF and RS) were to assess each study independently looking at
he following criteria:
• sequence generation (confounding);
• allocation concealment (information bias): we planned to
summarise how allocation sequences were generated and to
report any attempts to conceal allocation of assigned
intervention, along with any judgements concerning the risk of
bias that may have arisen from the methods used;
• blinding for participants, personnel and outcome
assessment (performance and detection bias): a brief summary of
who was blinded or masked during the conduct and analysis of
the studies;
• incomplete outcome data (attrition or selection bias):
review authors’ concerns over exclusion of participants and
excessive (or differential) drop-out rates;
• selective reporting (reporting bias): we would have
summarised any concerns over the selective availability of data,
including evidence of selective reporting of outcomes, time-
points, subgroups or analyses;
• other bias(es) identified.
We planned to present a ’risk of bias’ summary figure, which rep-
resents all bias assessment points in a table format.
Measures of treatment effect
For dichotomous data, we planned to present results as summary
risk ratios (RR) with 95% confidence intervals (CI). For contin-
uous data, when outcomes were measured the same way in dif-
ferent trials, we planned to use the mean difference (MD). We
planned to use the standardised mean difference to combine trials
that measured the same outcome, but used different methods of
measurement (SMD). Time to complete wound healing was time-
to-event data. It was proposed that the most appropriate way of
summarising it was to use methods of survival analysis and to ex-
press the intervention effect as a hazard ratio. It is not appropriate
to analyse time-to-event data using methods used for continuous
outcomes (e.g. using mean times-to-event), as the relevant times
were only known for the subset of participants who have had the
event. Censored participants were to be excluded, which, almost
certainly, would have introduced bias.We planned to discuss time-
to-event data that had been presented incorrectly as continuous
data narratively, rather than as an analysis (Deeks 2011).
Unit of analysis issues
We planned to identify the unit of analysis used in each individual
study in relation to a wound, a foot, a participant or as multiple
wounds on the same participant.Wewouldhave recorded if studies
had incorrectly treated multiple wounds on a participant as being
independent, rather than using within-patient analysis methods,
in the risk of bias assessment. For wound healing and amputation,
unless otherwise stated, where the number of wounds appeared
to equal the number of participants, we would have treated the
wound as the unit of analysis. We planned to treat these studies
with caution.Weplanned to include them in the systematic review,
but to conduct meta-analysis with and without them in sensitivity
analyses, to assess the effect they would have had on the results.
We also planned to assess the level of randomisation of each trial
to see whether the number of observations matched the number
of units randomised. Where the unit of analysis was unclear, we
would have contacted the trial author for results per person.
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Weplanned to assess the unit of analysis for adverse event data on a
trial-by-trial basis to establish whether the data were at participant
level, or whether multiple events per participant were possible.
Where the latter was the case, although the data could be reported
on a trial by trial basis, they could not be analysed further without
violating assumptions of independence. We planned to discuss
the method of data collection, potential risks of measurement and
performance biases, as well as the unit of analysis of adverse event
data in detail in the review.
If multiple treatment arms were reported, we planned to carry out
multiple meta-analyses. If more than one control group was used
or where a single ’conventional’ control group was not recognis-
able, we planned to combine all control group results and carry
out pooled analyses of all control groups against the intervention
group.
In relation to the inclusion of cluster RCTs, we planned to attempt
analysis where relevant information was available (i.e. the number,
or mean size, of clusters, outcome data for total individuals with
events, and an estimate of the intra-cluster/intra-class correlation
coefficient (ICC). A more reliable analysis was then going to be
conducted by reducing the size of each trial to its effective sam-
ple size using the design effect of a cluster RCT, and the standard
error obtained from confidence intervals, as recommended by the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011b). Potential meta-analysis could therefore have been per-
formed using the inflated variances.
Dealing with missing data
We planned to seek missing information from the original trial
authors by emailing the contact person for the published studies.
In particular, we would have contacted the authors for the rele-
vant data where the reported findings of a study extended beyond
foot ulcers and it would have been difficult to determine which,
if any, findings related to foot ulcers specifically. When responses
were not received, we were to contact additional authors from the
publication. To avoid overly positive answers and the risk of false
information, we planned to use open-ended questions for contact-
ing authors (Higgins 2011b). If information relating to outcomes
(according to outcome measures) was missing, we deemed the ar-
ticle unsuitable for the review.
Multiple efforts were made to acquire any missing data from au-
thors. We planned to inspect factors such as attrition rates, drop-
out rates, randomised and included subject numbers, as well as
numbers for intention-to-treat, treated-per-protocol and losses to
follow-up carefully. We would have appraised these critically and
assessed their impact on the data in the light of the results of the
review.
We acknowledged that sometimes measures of dispersion are not
recorded in trials. Where the standard error (SE) or the t-statistic
was reported, we planned to calculate standard deviations with
statistical assistance from review author, PB. Where the authors
did not report the aetiology of ulcers, we planned to contact them
for details. Where the authors were unable to confirm aetiology,
we would have excluded the study.
Assessment of heterogeneity
Clinical heterogeneity
We planned to determine potential reasons for heterogeneity by
exploring individual study and subgroup characteristics such as
age and gender of participants, risk factors for foot ulceration, du-
ration of disease, initial size of ulcer, type of treatment, duration of
follow-up, presence or absence of infection, history of ulceration,
history of significant cardiovascular events, presence or absence of
PAD, type of ulcer, location of ulcer, time to ulcer healing, type of
medication used, as well as how ulcer healing was defined within
the context of the study.
Methodological heterogeneity
We planned to use the formal assessment of bias of each study,
as described above, to assist in identifying methodological hetero-
geneity between studies.
Statistical heterogeneity
We planned to use forest plots, Q and I2 statistics to assess het-
erogeneity (Higgins 2003). If heterogeneity was present, then we
aimed to identify the studies that produced it, and to conduct an
analysis without them. The Q-statistic assessed for the presence of
heterogeneity (Higgins 2003). With the I2 statistic, values of 75%
or more were taken as indicative of high levels of heterogeneity
(Deeks 2011).
Only those studies that were clinically, methodologically and sta-
tistically homogenous were to be pooled for meta-analysis effect-
size calculations. We planned to define subgroups for analysis us-
ing the factors we identify above as being responsible for hetero-
geneity.
Assessment of reporting biases
If there was a sufficient number of studies (10 or more) available,
we planned to use funnel plots to assess publication bias. If there
were not enough studies in the meta-analysis for constructing a
meaningful funnel plot, we would have discussed the potential for
publication bias using available studies (Sterne 2011).
Data synthesis
We consulted the Cochrane Collaboration recommendations and
decided to conduct both random-effects and fixed-effect models
where appropriate for any potential meta-analysis. For example
10Intensive versus conventional glycaemic control for treating diabetic foot ulcers (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
where clinical, methodological and statistical heterogeneity were
not apparent, we planned to pool similar studies in a fixed-effect
model. Where any of the above-mentioned heterogeneity was ev-
ident we would have used a random-effects model. Where het-
erogeneity levels were insignificant and no other forms of hetero-
geneity were evident, we would have used both random-effects
and fixed-effect models for comparison. We planned to attempt
to investigate any significant differences in results and heterogene-
ity of studies through use of these two statistical models. If there
were any vast differences between the two methods, we planned
on exploring these differences. If fixed-effect and random-effects
meta-analyses gave identical results, then we thought that it was
unlikely that there was important statistical heterogeneity, and we
believed either method was appropriate for reporting.We planned
to include all studies meeting the inclusion criteria and reporting
outcome variables of interest in the review and we would have in-
cluded all studies meeting eligibility criteria for meta-analysis in a
meta-analysis. We planned to conduct meta-analysis separately on
provided and published data, and also on results from intention-
to-treat trials. We would have used Review Manager (RevMan
2014)for data analysis.
’Summary of findings’ tables
We would have presented the main results of the review in ’Sum-
mary of findings’ tables. These tables present key information con-
cerning the quality of the evidence, the magnitude of the effects
of the interventions examined, and the sum of the available data
for the main outcomes (Schünemann 2011a). The ’Summary of
findings’ tables also include an overall grading of the evidence re-
lated to each of the main outcomes using the GRADE (Grades
of Recommendation, Assessment, Development and Evaluation)
approach. The GRADE approach defines the quality of a body of
evidence as the extent to which one can be confident that an esti-
mate of effect or association is close to the true quantity of specific
interest. The quality of a body of evidence involves consideration
of within-trial risk of bias (methodological quality), directness of
evidence, heterogeneity, precision of effect estimates and risk of
publication bias (Schünemann 2011b).We planned to present the
following outcomes in the ’Summary of findings’ tables:
• Number of ulcers healed
• Time to complete ulcer healing
• Change in ulcer severity
• Incidence of amputation related to foot ulcers.
Subgroup analysis and investigation of heterogeneity
Weplanned subgroup analyses at several levels in themeta-analysis.
We would have decided the subgroups after consideration of a
number of factors, based on:
• Follow-up time: studies stratified as short, medium and
long term, where less than one year of follow-up was to be
considered as short term, one to three years as medium term, and
more than three years as long term;
• Variation in the intervention and control group (e.g. groups
who received lifestyle interventions versus anti-diabetic
medication versus insulin).
Sensitivity analysis
We planned to carry out sensitivity analyses by excluding and
including studies that caused heterogeneity in the data. We also
planned to carry out sensitivity analyses by excluding and includ-
ing studies that were deemed to be of lower quality (high risk of
bias). We planned to discuss the results of the sensitivity analyses.
R E S U L T S
Description of studies
See Characteristics of included studies,Characteristics of excluded
studies and Characteristics of ongoing studies.
Results of the search
Our final database search identified 18,792 records in total. A fur-
ther 726 records were identified by searching clinical trials regis-
ters, pharmaceutical trials registers and by looking through cur-
rently available clinical guidelines (see Figure 1). After the removal
of duplicates, the review authors screened 7994 records for inclu-
sion based on the title and abstract matching the review inclusion
criteria. This screening process further excluded 7945 articles.MF
and RS reviewed 49 trials from full-text articles or online trial reg-
istrations which were considered potentially eligible for inclusion
based on the inclusion criteria. The most recent database and clin-
ical trial registry searches were carried out in December 2015.
We found two ongoing registered trials (NCT01472432 and
ACTRN12613000418774) which were of potential interest (see
Characteristics of ongoing studies). These are both investigating
the effect of dipeptidyl peptidase-4 (DPP-4) inhibitors (specifi-
cally vildagliptin) on foot ulcer outcomes. No results have been
published from these trials to date, however the study protocols
are published in clinical trials registries.
The first ongoing trial (NCT01472432) is investigating the clin-
ical and humoral effects of vildagliptin on healing of chronic
ulcers in people with type 2 diabetes. The experimental group
in this trial will receive vildagliptin 50 mg orally twice a day
for four months.The placebo group will receive oral antidia-
betic therapy titrated for optimal glycaemic control for three
months. The primary outcome measure is full epithelisation of
the wound within four months and capillary density on punch
biopsy before and after the treatments. The second ongoing
trial (ACTRN12613000418774) is investigating the effects of
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vildagliptin on inflammation markers in people with type 2 dia-
betes with foot ulcers. The intervention group receive oral met-
formin with the addition of vildagliptin for 12 weeks: the dose
being determined by fasting blood glucose levels with the aim of
achieving fasting glucose levels < 7 mmol/l and postprandial levels
of < 10 mmol/l. The second group receive a similar dose of met-
formin and receive a placebo instead of vildagliptin. This trial has
listed partial and complete wound closure within 12 weeks as a
secondary outcome measure.
Included studies
The only eligible study which met the inclusion criteria was a
pilot trial which was undertaken to determine the feasibility of
performing a definitive trial assessing the effect of close glycaemic
control on healing foot ulcers in people with diabetes (Idris 2004).
This pilot study was prematurely terminated due to difficulty in
participant recruitment. No data was reported and so we were
unable to obtain any data from this trial; see Characteristics of
included studies.
Excluded studies
A list of all excluded trials can be found here (see Characteristics of
excluded studies). Out of the 49 trials screened for inclusion, 46
were excluded (see Characteristics of excluded studies for reasons
of exclusion). Eight studies were excluded because we couldn’t con-
tact authors to obtain clarification on outcome measures, or where
outcomemeasures were not reported (Abraira 1992; Abraira 2003;
Calles-Escandon 2010; Duckworth 2009; Gaede 2003; Nathan
2009; UK Prospective Diabetes Study (UKPDS) Group 1998;
Van Olmen 2013). Another study (Zhang 2011) investigated the
effect of normal subcutaneous insulin injections in comparison
to injecting half the dose of insulin at the ulcer-site as a localised
treatment and half subcutaneously, over a period of seven days.
The trialists found an improvement in ulcer healing in the lo-
calised injection group with comparable fasting glucose levels, as
the control group receiving the same dose of insulin. This study
was published in Chinese and was translated. We excluded this
study as it was not designed to compare intensive versus conven-
tional glycaemic control on foot ulcer outcomes, especially foot
ulcer healing.
A further two trials were excluded due to non-randomisation
(Sullivan 2009; Kostev 2012) and another trial due to premature
termination (ACTRN12606000426583). We contacted the trial
author of ACTRN12606000426583 and the authors were able to
confirm that this study had been terminated before commence-
ment. Eighteen trials were excluded due to foot ulcer outcomes
not being investigated as an outcome measure (see Characteristics
of excluded studies). One trial Marso 2013 reported foot ulcers as
a tertiary study outcome on their protocol, yet no data has been
reported in relation to this outcome. Authors of the trial were
unable to provide us with any data on foot ulcer outcomes when
contacted. Therefore we also excluded this study. A further fif-
teen trials were excluded because participants were not exclusively
placed in intensive versus conventional glycaemic control arms, as
per the requirement for this review (see Characteristics of excluded
studies).
Risk of bias in included studies
We could not determine the risk of bias from the prematurely
terminated included trial (Idris 2004). See Risk of bias in included
studies.
Effects of interventions
One eligible study was identified however this provided no data.
D I S C U S S I O N
This systematic review aimed to assess the effects of intensive gly-
caemic control compared to conventional control on the treat-
ment of foot ulcers in people with type 1 and type 2 diabetes.
We performed an exhaustive search of evidence which consisted of
both published and unpublished material. Despite these efforts,
we were unable to find any clinical trials which had successfully
investigated the impact of intensive versus conventional glycaemic
control on foot ulcer outcomes. We found one trial which was
completed without any results (Idris 2004) and two ongoing tri-
als (ACTRN12613000418774; NCT01472432) which were in-
vestigating intensive versus conventional glycaemic control, and
which may report foot outcomes at a later date.
Although Idris 2004 cannot contribute to current evidence due to
a lack of results, there were several noteworthy points which were
made by the authors. The authors of this study faced challenges
in recruiting and allocating patients. A number of patients were
frail or thought to be incapable of adhering to intensive glycaemic
control. Recruitment is a challenge for any researcher recruiting
patients to a trial of intensive diabetes control for a number of
reasons.The authors reported that the attitude of people with foot
ulcers towards participating in a study involving intensive gly-
caemic control was negative despite the potential clinical benefit.
We believe factors such as the number of additional clinical con-
sultations needed, treatment compliance and participants’ ability
to endure potential side effects of intensive glycaemic control may
have adversely impacted on recruitment. The additional ethical
clinical dilemma faced by any modern day study investigating the
effects of intensive versus conventional glycaemic control is the
strong precedent set by major landmark trials such as the UKPDS
(UK Prospective Diabetes Study (UKPDS) Group 1998). These
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studies demonstrated a strong incentive for optimised glycaemic
control. This would be especially important for a trial assessing
foot ulcer healing, which is believed to be strongly influenced by
hyperglycaemia. Although there remains a clear need to document
the benefits associated with attempts to improve glycaemic control
in this population, the perceived cost and adverse events of such
a treatment needs to be taken into account in an older vulnerable
population prone to the effects of hypoglycaemia.
It is interesting to note that many of the trials investigating inten-
sive versus conventional glycaemic control screened in this review
included lower limb amputation as an outcomemeasure (Althouse
2013; Christiansen 2009; Dormandy 2005; Gaede 2003; Nathan
2009; Pedersen 2003; Vaccaro 2012). This outcomewas not, how-
ever, reported in relation to presentation with, development of,
or healing of foot ulceration. Amputation was likely used rather
than ulcer healing due to the ease of measurement and definitive
nature of such a procedural end-point. The clinical outcome of
ulcer healing has several different definitions available in the lit-
erature and is considered more labour intensive to measure than
amputation outcomes. Given that ulceration precedes lower limb
amputations in up to 85% of people with diabetes who have am-
putations (Boulton 2004; Singh 2005), it would seem logical that
successful ulcer healing could prevent the clinical progression to-
wards amputation and hence be of clinical significance. None of
the trials which were screened included amputation in patients
who had presented with foot ulcers as a specific outcome. Amputa-
tions were reported in relation to aetiological factors, such periph-
eral artery disease (Gaede 2003) and neuropathy (which was not
well-defined) Nathan 2009, or the cause was entirely undefined
(Althouse 2013;Christiansen 2009).One trial reported above-the-
ankle amputations but skin lesions were not documented (Vaccaro
2012). The authors of the screened trials were unable to provide
further information or data on how many amputations occurred
subsequent to a foot ulcer. Therefore we were unable to include
these trials.
As foot ulceration often precedes amputation, we believe future
trials should report on ulcer-specific outcomes. It has previously
been reported that the combination of patient-specific, limb-spe-
cific and ulcer-specific measures should be used as outcome mea-
sures in trials focusing on diabetic foot complications and clini-
cal care (Jeffcoate 2004). Furthermore, the use of amputation as
a stand-alone outcome measure of ulcer healing has been ques-
tioned and needs to be carefully considered (Margolis 2013). From
a patient and HRQoL point of view, foot ulcer healing may be
seen as a beneficial outcome over a detrimental endpoint such as
amputation. For example, in a previous meta-analysis, intensive
glycaemic control reduced the risk of amputation by 36% in peo-
ple with type 2 diabetes (relative risk (RR) 0.64, 95% CI: 0.43
to 0.95; 6960 participants in eight trials) (Hemmingsen 2011b).
Unfortunately this information was based on amputations defined
in several different ways. The underlying cause of amputation var-
ied in the trials and included a mix of ischaemic and neuropathic
aetiologies. The UKPDS, which contributed almost half of the
reported events in this analysis, defined amputation as major limb
complications requiring lower limb amputation of a digit or any
limb for any reason and included digital amputations which are
usually classified as minor amputations (UKPDS 1998). In other
trials the definition of amputation has been less clear. For example
it has not been clear whether minor (such as digital amputation)
were grouped together with major (such as below knee) ampu-
tations (Hemmingsen 2011b). Overall the authors of this meta-
analysis concluded that the data provided low level evidence for a
significantly reduced risk of amputation of a lower extremity us-
ing intensive glycaemic control (Hemmingsen 2011b). This was
based on the GRADE scoring system which indicates that further
research is very likely to have an important impact on the con-
fidence in the estimate of effect and is likely to change the esti-
mate. Other limitations in this analysis included the inability to
stratify the number of reported amputations according to cause of
amputation and the overall low number of reported amputations.
Although this data provides evidence to support the efficacy of in-
tensive glycaemic control in preventing amputations, its exact re-
lationship to foot ulcer healing remains unanswered. Studies have
recommended that outcomes such as ulcer-free survival time, ul-
cer recurrence rate and time to ulcer healing should also be docu-
mented in clinical studies as these give important information re-
garding the overall effectiveness of an intervention (Jeffcoate 2006;
Margolis 2013; Pound 2004).
There are a plethora of factors which we believe contribute to the
difficulty in performing an effective clinical trial on this partic-
ular topic and we would like to highlight a few of these which
we consider to be important. There are many factors determin-
ing ulcer healing (see Table 1) which makes it challenging to in-
vestigate the impact of one variable while keeping other factors
consistent. The first challenge is thus in effective randomisation
with appropriate stratification of these additional risk predictors.
Other determinants of ulcer healing need to be kept consistent in
the intervention and control groups. Each ulcer typically involves
slightly different treatments such as antibiotics, ulcer dressing and
offloading, which is challenging to standardise taking into account
the participants’ clinical requirements. At best a trial in a group
of participants receiving multiple treatments can only provide a
measure of the effect of a particular management intention.There
is an added issue that some people have more than one ulcer on
the same or different legs. These ulcers may respond to treatment
differently. Additionally, ulcer recurrence and new ulceration are
also a possibility during follow-up. This needs to be taken into
account when defining the outcome measures for such a trial.
The presence of infection further complicates this clinical scenario
and may have a profound impact on glycaemic control. Addition-
ally, a trial investigating intensive versus conventional glycaemic
control on foot ulcer outcomes needs to be able to observe an
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immediate effect of glycaemic control which will assist with foot
ulcer healing, rather than observing long term glycaemic improve-
ments, which is often the aim of clinical trials investigating gly-
caemic control. Therefore utilising mean blood glucose instead
of HbA1c may be preferable in such a trial due to the ability to
observe more immediate changes in glycaemic control.
Lastly and perhaps most importantly, we believe that there is also
a major sample size challenge to designing a trial in this area.
Previous trials investigating the effect of intensive versus conven-
tional glycaemic control on microvascular end points contained
large sample sizes and used multiple study centres for recruit-
ment. For example the ADVANCE trial (ADVANCE 2008) re-
cruited from 215 different study centres and had 11,140 partici-
pants, and the UKPDS (UKPDS 1998) recruited from 23 differ-
ent study centres and had 5102 participants randomised to two
groups. Although the difference in glycaemic control needed to
demonstrate a significant statistical effect on ulcer healing is un-
known, clinical guidelines recommend narrow glucose differences
between intensive and conventional arms (see Table 2). Thismight
mean that large sample sizes involving multiple centres may be re-
quired to provide adequate statistical power to observe significant
differences in ulcer healing. As amputation is a binary outcome
measure and as ulcer healing can be a numerical outcome mea-
sure (i.e. reduced ulcer area), it would seem plausible that sample
sizes adequate for amputation outcomes should be sufficient for
investigating foot ulcer healing. Appropriate sample size calcula-
tions based on multiple outcomes are however needed to under-
stand the true extent of intensive glycaemic control on foot ul-
cer outcomes. Whether or not the two trials that are currently in
progress (ACTRN12613000418774; NCT01472432) will ulti-
mately have enough statistical power is yet to be observed. One
trial (ACTRN12613000418774) has reported a proposed sample
size of only 50, which suggests it is likely to be underpowered to
assess the effect of the intervention on ulcer outcomes.
The eligibility of these ongoing trials for future inclusion in this
review depends on a number of factors. Most importantly this will
be based on whether glycaemic levels of the intervention and con-
trol groups differ. Successful, partial or complete wound healing
also needs to be observed in the trials in order to assess a rela-
tionship between glycaemic control and wound healing within the
reported time-frames of the trials. The authors of both trials have
been contacted to obtain any data which may become available at
a later date.
In conducting this review, we have made exhaustive efforts to con-
tact researchers and manufacturers of pharmaceutical agents who
may have investigated foot ulcer outcomes. We do acknowledge
the difficulties in identifying unpublished data and accept that
some unpublished work may have been missed. It is also possible
that literature published in languages other than English may have
been missed. We intentionally did not exclude studies on the ba-
sis of language. We found two non-English studies amid the full-
text trials screened for eligibility. One trial was in Chinese (Zhang
2011) and one was in German (Fresenius 2009). These were trans-
lated into English for assessment and the original authors were
contacted for any clarification.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The current review failed to find any randomised clinical trials
with results. Therefore we are unable to conclude whether inten-
sive glycaemic control when compared to conventional glycaemic
control has a positive or detrimental effect on the treatment of foot
ulcers.The exact role and place that intensive glycaemic control
may have on treating foot ulcers remains to be resolved.
Implications for research
Independent, well-designed, large RCTs may be required to inves-
tigate the benefits and adverse effects of intensive versus conven-
tional glycaemic control on diabetic foot ulcer outcomes.Those
who are considering research in this area should consider the chal-
lenges of conducting a trial on this topic which have been out-
lined in the discussion. Ideally future RCTs investigating this topic
should be specifically designed and tailored to answer the question
of superiority of intensive over conventional glycaemic control. In
particular future research should aim to:
• consider ulcer-specific outcome measures (i.e. healing) in
addition to amputation;
• find ways to control, adjust or match for ulcer
characteristics, participant characteristics and the various
interventions required for optimal ulcer healing using
appropriate randomisation, adjustment or stratification;
• assess the role of intensive versus conventional glycaemic
control in predisposing to diabetic foot ulcer infection as well as
foot ulcer healing;
• have a sample size that is large enough to test a statistically
significant effect and be large enough to allow for subgroup
analyses.
A C K N OW L E D G E M E N T S
Firstly we would like to thank the librarians of Townsville Hospi-
tal, QueenslandHealth for assistance with literature searching and
sourcing full-text articles. We especially thank Mrs. Bronia Reni-
son (Senior Librarian, Townsville Hospital Library) for her time,
expertise and assistance with literature searches. We also thank
14Intensive versus conventional glycaemic control for treating diabetic foot ulcers (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Mr. Stephen Anderson (James Cook University Library) for assis-
tance with literature searches. A special thanks to Dr. Hongyou Yu
for his assistance with article translation. The review authors wish
to thank Cochrane Wounds for the opportunity given to us and
for the support provided. We would like to thank the following
peer referees for their feedback and suggestions in the construc-
tion of the protocol; Jo Dumville, Duncan Chambers, Richard
Kirubakaran, David Armstrong, Zena Moore, Nadine Madams
and Rachel Richardson and acknowledge Elizabeth Royle who
copy edited the protocol. We would like to thank the following
peer referees for their feedback and suggestions on the construc-
tion of the review; David Margolis, Richard Kirubakaran, David
Armstrong and Ankur Barua. Thanks also to and Denise Mitchell
who copy edited the review.
R E F E R E N C E S
References to studies included in this review
Idris 2004 {unpublished data only}
Idris I, Game F, Jeffocoate W. Does close glycaemic control
promote healing in diabetic foot ulcers? Report of a
feasibility study. Diabetic Medicine 2004;22:1060–63.
References to studies excluded from this review
Abraira 1992 {published data only (unpublished sought but not used)}
Abraira C, Emanuele N, Colwell J, Henderson W,
Comstock J, Seymor L, et al. Glycemic control and
complications in Type II diabetes: design of a feasibility
trial. Diabetes Care 1992;15(11):1560–71.
Abraira 2003 {published data only (unpublished sought but not used)}
Abraira C, Duckworth W, McCarren M, Emanuele N,
Arca D, Reda D, et al. Design of the cooperative study on
glycemic control and complications in diabetes mellitus
type 2: Veterans Affairs Diabetes Trial. Journal of Diabetes
and Its Complications 2003;17:314–22.
ACTRN12606000426583 {unpublished data only}
Ogrin R. Non-weight bearing exercise in people with
diabetes and foot complications. http://www.anzctr.org.au/
(accessed 10 April 2015).
Althouse 2013 {published data only}
Althouse A, Abbott J, Sutton-Tyrrell K, Forker A,
Lombardero M, Buitron L, et al. Favorable effects of
insulin sensitizers pertinent to peripheral arterial disease
in Type 2 diabetes: results from the Bypass Angioplasty
Revascularization Investigation 2 Diabetes (BARI 2D) trial.
Cardiovascular and Metabolic Risk 2013;36:3269–75.
Bayat 2013 {published data only}
Bayat F, Shojaeezadeh D, Baikpour M, Heshmat R,
Baikpour M, Hosseini M. The effects of education based on
extended health belief model in type 2 diabetic patients: a
randomized controlled trial. Journal of Diabetes & Metabolic
Disorders 2013;12(45):1–6.
Bloomgarden 1987 {published data only (unpublished sought but not
used)}
Bloomgarden Z, Karmally W, Metzger J, Brothers M,
Nechemias C, Bookman J, et al. Randomized, controlled
trial of diabetic patient education: improved knowledge
without improved metabolic status. Diabetes Care 1987;10
(3):263–72.
Boaz 2009 {published data only}
Boaz M, Hellman K, Wainstein J. An automated
telemedicine system improves patient-reported well-being.
Diabetes Technology and Therapeutics 2009;11(3):181–6.
Calles-Escandon 2010 {published data only (unpublished sought but
not used)}
Calles-Escandon J, Lovato L, Simons-Morton D, Kendall
D, Pop-Busui R, Cohen R, et al. Effect of intensive
compared with standard glycemia treatment strategies on
mortality by baseline subgroup characteristics: the Action to
Control Cardiovascular Risk in Diabetes (ACCORD) trial.
Diabetes Care 2010;33:721–7.
Chiu 2011 {published data only}
Chiu CC, Huang CL, Weng S-F, Sun LM, Chang YL,
Tsai FC. A multidisciplinary diabetic foot ulcer treatment
programme significantly improved the outcome in patients
with infected diabetic foot ulcers. Journal of Plastic,
Reconstructive & Aesthetic Surgery 2011;64:867–72.
Christiansen 2009 {published data only (unpublished sought but not
used)}
Christensen L, Almdal T, Boesgaard T, Breum L, Dunn E,
Gade-Rasmussen B, et al. Study rationale and design of
the CIMT trial: The Copenhagen Insulin and Metformin
Therapy trial. Diabetes, Obesity and Metabolism 2009;11:
315–22.
Clark 2001 {published data only}
Clark C, Snyder J, Meek R, Stutz L, Parkin C. A systematic
approach to risk stratification and intervention within a
managed care environment improves diabetes outcomes and
patient satisfaction. Diabetes Care 2001;24:1079–86.
15Intensive versus conventional glycaemic control for treating diabetic foot ulcers (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Dormandy 2005 {published data only}
Dormandy J, Charbonnel B, Eckland D, Erdmann E,
Massi-Benefetti M, Moules I, et al. Secondary prevention
of macrovascular events in patients with type 2 diabetes in
the PROactive Study (PROspective pioglitAzone Clinical
Trial In macroVascular Events): a randomised controlled
trial. Lancet 2005;366(9493):1279–89.
Duckworth 2009 {published data only (unpublished sought but not
used)}
Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N,
Reaven P, et al. Glucose control and vascular complications
in veterans with type 2 diabetes. The New England Journal
of Medicine 2009;360(2):129–39.
Fresenius 2009 {published data only (unpublished sought but not
used)}
Fresenius K, Framer I. Implementation and evaluation of
pharmaceutical care on the outcomes of patients suffering
from diabetic foot syndrome. Krankenhauspharmazie 2009;
30(1):2–10.
Gaede 2003 {published data only (unpublished sought but not used)}
Gaede P, Vedel P, Larsen N, Gunnar V, Jensen G, Parving
H, et al. Multifactorial intervention and cardiovascular
disease in patients with type 2 diabetes. The New England
Journal Of Medicine 2003;348(5):383–93.
Gaede 2006 {published data only}
Gaede P. Intensified multifactorial intervention in patients
with type 2 diabetes and microalbuminuria: rationale
and effect on late-diabetic complications. Danish Medical
Bulletin 2006;53:258–84.
Garber 2002 {published data only}
Garber A, Larsen J, Schneider S, Piper B, Henry D on behalf
of The Glyburide/Metformin Initial Therapy Study Group.
Simultaneous glyburide/metformin therapy is superior to
component monotherapy as an initial pharmacological
treatment for type 2 diabetes. Diabetes, Obesity and
Metabolism 2002;4:201–8.
Gram 2011 {published data only}
Gram J, Henriksen J, Grodum E, Juhl H. Hansen R,
Christiansen C, et al. Pharmacological treatment of the
pathogenetic defects in type 2 diabetes: the randomized
multicenter South Danish diabetes study. Diabetes Care 34;
1:27–33.
Griffin 2011 {published data only}
Griffin S, Knut B, Davies M, Khunti K, Rutten G.
Effect of early intensive multifactorial therapy on 5-year
cardiovascular outcomes in individuals with type 2 diabetes
detected by screening (ADDITION-Europe): a cluster-
randomised trial. Lancet 2011;378:156–67.
Jarnert 2012 {published data only}
Jarnert C, Kalani M, Ryden L, Bohm F. Strict glycaemic
control improves skin microcirculation in patients with
type 2 diabetes: a report from the Diabetes mellitus And
Diastolic Dysfunction (DADD) study. Diabetes & Vascular
Disease Research 2012;9(4):287–95.
Kawamori 2010 {published data only}
Kawamori R. Evidence demonstrating the effects of anti-
atherosclerotic actions of pioglitazone - special emphasis on
PROactive Study and PERISCOPE Study. Japanese Journal
of Clinical Medicine 2010;68(2):235–41.
Kostev 2012 {published data only}
Kostev K, Dippel FW, Rockel T, Siegmund T. Risk of
diabetic foot ulceration during treatment with insulin
glargine and NPH insulin. Journal of Wound Care 2012;21:
483–9.
Leung 2012 {published data only}
Leung P, Pang S, Wong E, Cheng K. Inflammatory state of
Type II diabetic patients with chronic ulcers in response to
herbal treatment. The Foot 2012;22(3):181–5.
Li 2008 {published data only}
Li Y, Song ZR, Ren HZ. Alprostadil combined with
deproteinized calf blood extractives injection for treatment
of diabetic foot. Journal of Clinical Rehabilitative Tissue
Engineering Research 2008;12:9970–2.
Litzelman 1993 {published data only}
Litzelman D, Slemenda C, Langefeld C, Hays L, Welch
M, Bild D, et al. Reduction of lower extremity clinical
abnormalities in patients with non-insulin-dependent
diabetes mellitus. A randomized, controlled trial. Annals of
Internal Medicine 1993;119(1):36–41.
Marso 2013 {published data only}
Marso S, Poulter N, Nissen S, Nauck M, Zinman B,
Daniels G, et al. Design of the liraglutide effect and
action in diabetes: evaluation of cardiovascular outcome
results (LEADER) trial. American Heart Journal 2013;166:
823–30.
Martinez-Sanchez 2005 {published data only (unpublished sought but
not used)}
Martinez-Sanchez G, Al-Dalain S, Menendez S, Giuliani
L, Candelario-Jalil E, Alvarez H, et al. Therapeutic efficacy
of ozone in patients with diabetic foot. European Journal of
Pharmacology 2005;523:151–61.
McMurray 2002 {published data only}
McMurray S, Johnson G, Davis S, McDougall K. Diabetes
education and care management significantly improve
patient outcomes in the dialysis unit. American Journal of
Kidney Diseases 2002;40(3):566–75.
Meigs 2003 {published data only}
Meigs J, Cagliero E, Dubey A, Murphy-Sheehy P,
Gildesgame C, Chueh H. A controlled trial of web-based
diabetes disease management: the MGH diabetes primary
care improvement project. Diabetes Care 2003;26(3):
750–7.
Nathan 2009 {published data only}
Nathan D, Zinman B, Cleary P, Blacklund J, Genuth S,
Miller R, et al. Modern-day clinical course of type 1 diabetes
mellitus after 30 years’ duration: the Diabetes Control and
Complications trial/Epidemiology of Diabetes Interventions
and Complications and Pittsburgh Epidemiology of
Diabetes Complications Experience. Archives of Internal
Medicine 2009;169(14):1307–16.
16Intensive versus conventional glycaemic control for treating diabetic foot ulcers (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
NCT00850798 {unpublished data only}
Chen HS, Lin H. The benefits of intensive glycemic
control in elderly patients with type 2 diabetes. https://
clinicaltrials.gov/ct2/show/NCT00850798 (accessed 10
April 2015).
NCT01421966 {unpublished data only}
Macrocure Ltd. Evaluation of CureXcell® in treating lower
extremity chronic ulcers in adults with diabetes. https:/
/clinicaltrials.gov/ct2/show/NCT01421966 (accessed 10
April 2015).
NCT01813305 {unpublished data only}
Charsire Biotechnology Corp. CSTC1 for diabetic foot
ulcers phase II study. https://clinicaltrials.gov/ct2/show/
NCT01813305 (accessed 10th April 2015).
Nybo 2011 {published data only}
Nybo M, Preil SR, Juhl H, Olesen M, Yderstraede K,
Gram J, et al. Rosiglitazone decreases plasma levels of
osteoprotegerin in a randomized clinical trial with type
2 diabetes patients. Basic & Clinical Pharmacology &
Toxicology 2011;109:481–5.
Pedersen 2003 {published data only}
Pedersen O, Gaede P. Intensified multifactorial intervention
and cardiovascular outcome in type 2 diabetes: the Steno-
2 study. Metabolism: clinical and experimental 2003;52(8):
19–23.
Rong 2012 {published data only}
Rong L, Xia D, Luo Z, Aimin Z, Cao M. Two-year foot care
program for minority patients with type 2 diabetes mellitus
of Zhuang Tribe in Guangxi, China. Canadian Journal of
Diabetes 2012;36(1):8–5.
Sullivan 2009 {published data only}
Sullivan S, Alfonso-Cristancho R, Conner C, Hammer M,
Blonde L. Long-term outcomes in patients with type 2
diabetes receiving glimepiride combined with liraglutide or
rosiglitazone. Cardiovascular Diabetology 2009;8(12):1–9.
Timlin 2010 {published data only}
Timlin L, Beaudet A, WIlson B, Bruhn D, Boye J, Palmer J,
et al. Long-term clinical outcomes of exenatide once-weekly
versus insulin glargine for the treatment of type 2 diabetes
projected using the core diabetes model. Value in health
2010 Conference: ISPOR 13th Annual European Congress
Prague Czech Republic. Prague Czech Republic.: ISPOR,
2010; Vol. Conference Publication:284–85.
UK Prospective Diabetes Study (UKPDS) Group 1998 {published
data only}
UK Prospectice Diabetes Study (UKPDS) Group. Intensive
blood-glucose control with sulphonylureas or insulin
compared with conventional treatment and risk of
complications in patients with type 2 diabetes (UKPDS
33). Lancet 1998;352:837–53.
Vaccaro 2012 {published data only}
Vaccaro O, Masulli M, Bonora E, Del Prato S, Giorda
C, Maggioni A P, et al. Addition of either pioglitazone
or a sulfonylurea in type 2 diabetic patients inadequately
controlled with metformin alone: impact on cardiovascular
events. A randomized controlled trial. Nutrition,
Metabolism & Cardiovascular Diseases 2012;22:997–1006.
Vadstrup 2009 {published data only}
Vadstrup E, Frolich A, Perrild H, Borg E, Roder M. Lifestyle
intervention for type 2 diabetes patients - trial protocol of
The Copenhagen Type 2 Diabetes Rehabilitation Project.
BMC Public Health 2009;9:1–8.
Van Olmen 2013 {published data only}
Van Olmen J, Ku GM, Van Pelt M, Kalobu J, Hen H,
Darras C, et al. The effectiveness of text messages support
for diabetes self-management: protocol of the TEXT4DSM
study in the democratic Republic of Congo, Cambodia and
the Philippines. BMC Public Health 2013;13:423–32.
Williams 2012 {published data only}
Williams ED, Bird D, Forbes A, Russell A, Ash S, Friedman
R, et al. Randomised controlled trial of an automated,
interactive telephone intervention (TLC Diabetes) to
improve type 2 diabetes management: baseline findings and
six-month outcomes. BMC Public Health 2012;12:602–13.
Zhang 2011 {published data only}
Zhang ZX, Liu X, Lu L, Zhang L, Di DL, Liu LH. Effect
of insulin by local injection on the level of systemic blood
glucose and granulation tissue formation of wound in
patients with diabetic foot ulcer. Chinese Journal of Burns
2011;27(6):451–5.
Zhang 2013 {published data only}
Zhang J, Burridge L, Baxter K, Donald M, Foster M,
Hollingworth S, et al. A new model of integrated primary-
secondary care for complex diabetes in the community:
study protocol for a randomised controlled trial. Trials
2013;14:382–91.
Zhenghua 2011 {published data only}
Zhenghua X, Dingyu C, Qiling Y, Qian Z, Jin X,
Chunling H, et al. Individualised diabetic education can
contribute to decrease the incidence of diabetic foot and
avoid amputation: results of a 9-year prospective study.
Diabetologia 2011;54:S32.
References to ongoing studies
ACTRN12613000418774 {unpublished data only}
Malabu UH. Effects of Galvus (vildagliptin) on interleukin-
6 in diabetic foot ulcer. https://www.anzctr.org.au/Trial/
Registration/TrialReview.aspx?id=364001 (accessed 10 April
2015).
NCT01472432 {published data only}
Marfella R. Dipeptidyl peptidase (DPP) IV inhibition
facilitates healing of chronic foot ulcers in patients
with type 2 diabetes. https://clinicaltrials.gov/ct2/show/
NCT01472432 (accessed 10 April 2015).
Additional references
ADA 2012
American Diabetes Association. Standards of medical care
in diabetes 2012. Diabetes Care 2012;35(Suppl 1):11–63.
17Intensive versus conventional glycaemic control for treating diabetic foot ulcers (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
ADVANCE 2008
ADVANCE Collaborative Group. Intensive blood glucose
control and vascular outcomes in patients with type 2
diabetes. New England Journal of Medicine 2008;358(24):
2560–72.
Apelqvist 1999
Apelqvist J, Larsson J. What is the most effective way
to reduce incidence of amputation in the diabetic foot?.
Diabetes/Metabolism Research and Reviews 1999;16(Suppl
1):75–83.
Armstrong 1998
Armstrong D, Lavery DC, Harkless L. Validation of a
diabetic wound classification system - the contribution
of depth, infection, and ischemia to risk of amputation.
Diabetes Care 1998;21(5):855–9.
Bagg 2001
Bagg W, Whalley GA, Gamble G, Drury PL, Sharpe N,
Braatvedt GD. Effects of improved glycaemic control on
endothelial function in patients with type 2 diabetes.
Internal Medicine Journal 2001;31(6):322–8.
Boulton 2004
Boulton AJM. The diabetic foot: from art to science: the
18th Camillo Golgi lecture. Diabetologia 2004;47(8):
1343–53.
Brownlee 2004
Brownlee M. The pathobiology of diabetic complications.
A unifying mechanism. Diabetes 2004;54(6):1615–25.
Burakowska 2006
Korzon-Burakowska A, Edmonds M. Role of the
microcirculation in diabetic foot ulceration. International
Journal of Lower Extremity Wounds 2006;5(3):144–8.
Cheung 2009
Cheung NW, Conn JJ, D’Emden MC, Gunton JE, Jenkins
AJ, Ross GP, et al. Position statement of the Australian
Diabetes Society: individualisation of glycated haemoglobin
targets for adults with diabetes mellitus. Medical Journal of
Australia 2009;191:339-44.
Christman 2011
Christman AL, Selvin E, Margolis DJ, Lazarus GS, Garza
LA. Hemoglobin A1c predicts healing rate in diabetic
wounds. Journal of Investigative Dermatology 2011;131(10):
2121–7.
Clayton 2009
Clayton W, Elasy TA. A review of the pathophysiology,
classification, and treatment of foot ulcers in diabetic
patients. Journal of Clinical Diabetes 2009;27(2):52–8.
Cook 2012
Cook JJ, Simonson DC. Epidemiology and health care
cost of diabetic foot problems. In: Veves A editor(s). The
Diabetic Foot: Medical and Surgical Management. Boston:
Contemporary Diabetes, 2012:17–32.
D’Souza 2009
D’Souza DR, Salib MM, Bennett J, Mochin-Peters M,
Asrani K, Goldblum SE, et al. Hyperglycemia regulates
RUNX2 activation and cellular wound healing through
the aldose reductase polyol pathway. Journal of Biological
Chemistry 2009;284(27):17947–55.
Daroux 2010
Daroux M, Prévost G, Maillard-Lefebvre H, Gaxatte C,
D’Agati VD, Schmidt AM, et al. Advanced glycation
end-products: implications for diabetic and non-diabetic
nephropathies. Diabetes and Metabolism 2010;36:1–10.
Deeks 2011
Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9:
Analysing data and undertaking meta-analyses. In: Higgins
JPT, Green S (editors).Cochrane Handbook for Systematic
Reviews of Interventions Version 5.1.0 (updated March
2011). The Cochrane Collaboration, 2011. Available from
www.cochrane-handbook.org.
Delamaire 1997
Delamaire M, Maugendre D, Moreno M, Le Goff MC,
Allannic H, Genetet B. Impaired leucocyte functions in
diabetic patients. Diabetic Medicine 1997;14(1):29–34.
Dinh 2005
Dinh TL, Veves A. A review of the mechanisms implicated
in the pathogenesis of the diabetic foot. International
Journal of Lower Extremity Wounds 2005;4(3):154–9.
Electronic Therapeutic Guidelines Australia 2012
ETG. Type 2 diabetes and cardiovascular disease risk.
Australian Electronic Therapeutic Guidelines http://
www.tg.org.au/etg˙demo/phone/tgc/cvg/951.htm (accessed
10 December 2012).
Endnote 2012
Endnote. http://endnote.com/. Thomson Reuters, 2012.
Falanga 2005
Falanga V. Wound healing and its impairment in the
diabetic foot. The Lancet 2005;366(9498):1736-43.
Game 2012
Game F. Choosing life or limb. Improving survival in the
multi-complex diabetic foot patient. Diabetes/Metabolism
Research and Reviews 2012;28(Suppl 1):97–100.
Geraldes 2010
Geraldes P, King GL. Activation of protein kinase C
isoforms and its impact on diabetic complications. Journal
of Circulation Research 2010;106(8):1319–31.
Giacco 2010
Giacco F, Brownlee M. Oxidative stress and diabetic
complications. Circulation Research 2010;107(9):1058–70.
Gupta 2010
Gupta SK, Panda S, Singh SK. The etiopathogenesis of the
diabetic foot: an unrelenting epidemic. The International
Journal of Lower Extremity Wounds 2010;9(3):127-31.
Hemmingsen 2011a
Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal T,
Hemmingsen C, et al. Intensive glycaemic control for
patients with type 2 diabetes: systematic review with meta-
analysis and trial sequential analysis of randomised clinical
trials. BMJ 2011;343:d6898.
18Intensive versus conventional glycaemic control for treating diabetic foot ulcers (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Hemmingsen 2011b
Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal
T, Hemmingsen C, et al. Targeting intensive glycaemic
control versus targeting conventional glycaemic control
for type 2 diabetes mellitus. Cochrane Database of
Systematic Reviews 2011, Issue 6. [DOI: 10.1002/
14651858.CD008143.pub2]
Higgins 2003
Higgins JPT, Thompson SG, Deeks JJ, Altman DG.
Measuring inconsistency in meta-analyses. BMJ 2003;327
(7417):557–60.
Higgins 2011a
Higgins JPT, Altman DG, Sterne JAC (editors). Chapter
8: Assessing risk of bias in included studies. In: Higgins
JPT, Green S (editors).Cochrane Handbook for Systematic
Reviews of Interventions Version 5.1.0 (updated March
2011). The Cochrane Collaboration, 2011. Available from
www.cochrane-handbook.org.
Higgins 2011b
Higgins JPT, Deeks J, Altman DG (editors). Chapter
16: Special topics in statistics. In: Higgins JPT, Green
S (editors), Cochrane Handbook for Systematic Reviews
of Interventions Version 5.1.0 (updated March 2011).
The Cochrane Collaboration, 2011. Available from
www.cochrane-handbook.org.
Hinchliffe 2012
Hinchliffe RJ, Andros G, Apelqvist J, Bakker K,
Friederichs S, Lammer J, et al. A systematic review of
the effectiveness of revascularization of the ulcerated foot
in patients with diabetes and peripheral arterial disease.
Diabetes/Metabolism Research and Reviews 2012;28(Suppl
1):179–217.
Hogg 2012
Hogg FR, Peach G, Price P, Thompson MM, Hinchliffe RJ.
Measures of health-related quality of life in diabetes-related
foot disease: a systematic review. Diabetologia 2012;55(3):
552–65.
IDF 2012
International Diabetes Federation. IDF diabetes atlas
update 2012. The global burden. http://www.idf.org/
diabetesatlas/5e/the-global-burden (accessed 10 December
2012).
Ikem 2010
Ikem R, Ikem I, Adebayo O, Soyoye D. An assessment of
peripheral vascular disease in patients with diabetic foot
ulcer. The Foot 2010;20(4):114–7.
Inzucchi 2012
Inzucchi SE, Bergenstal RM, Buse JB, Diamant
M, Ferrannini E, Nauck M, et al. Management of
hyperglycemia in type 2 diabetes: a patient-centered
approach: position statement of the American Diabetes
Association (ADA) and the European Association for the
Study of Diabetes (EASD). Journal of Diabetes Care 2012;
35(6):1364–79.
Jeffcoate 2004
Jeffcoate WJ, Price P, Harding KG, International Working
Group on Wound Healing and Treatments for People with
Diabetic Foot Ulcers. Wound healing and treatments
for people with diabetic foot ulcers. Diabetes/Metabolism
Research and Reviews 2004;20(Suppl 1):S78–89.
Jeffcoate 2006
Jeffcoate WJ, Chipchase SY, Ince P, Game FL. Assessing the
outcome of the management of diabetic foot ulcers using
ulcer-related and person-related measures. Diabetes Care
2006;29(1):1784–7.
Jones 2008
Jones RN, Marshall WP. Does the proximity of an
amputation, length of time between foot ulcer development
and amputation, or glycemic control at the time of
amputation affect the mortality rate of people with diabetes
who undergo an amputation?. Advances in Skin & Wound
Care 2008;21(3):118–23.
Lefebvre 2011
Lefebvre C, Manheimer E, Glanville J, on behalf of the
Cochrane Information Retrieval Methods Group. Chapter
6: Searching for studies. In: Higgins JPT, Green S
(editors). Cochrane Handbook for Systematic Reviews
of Interventions Version 5.1.0 [updated March 2011].
The Cochrane Collaboration, 2011. Available from
www.cochrane-handbook.org.
Ma 2009
Ma J, Yang W, Fang N, Zhu W, Wei M. The association
between intensive glycemic control and vascular
complications in type 2 diabetes mellitus: a meta-analysis.
Nutrition, Metabolism, and Cardiovascular Diseases: NMCD
2009;19(9):596–603.
Macisaac 2011
Macisaac RJ, Jerums G. Intensive glucose control and
cardiovascular outcomes in type 2 diabetes. Heart, Lung and
Circulation 2011;20(10):647–54.
Margolis 2013
Margolis DJ, Jeffcoate W. Epidemiology of foot ulceration
and amputation: can global variation be explained?. Medical
Clinics of North America 2013;97(1):791–805.
Mattila 2010
Mattila TK, De Boer A. Influence of intensive versus
conventional glucose control on microvascular and
macrovascular complications in type 1 and 2 diabetes
mellitus. Drugs 2010;70(17):2229–45.
Mazzone 2010
Mazzone T. Intensive glucose lowering and cardiovascular
disease prevention in diabetes reconciling the recent clinical
trial data. Circulation 2010;122:2201–11.
Moher 2009
Moher D, Liberati A, Tetzlaff J, Altman DG for the
PRISMA Group. Preferred reporting items for systematic
reviews and meta-analyses: the PRISMA statement. BMJ
2009;339:332–6. [DOI: 10.1371/journal.pmed.1000097]
19Intensive versus conventional glycaemic control for treating diabetic foot ulcers (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Nathan 2012
Nathan DM. Understanding the long-term benefits and
dangers of intensive therapy of diabetes. Archives of Internal
Medicine 2012;172(10):769–70.
NCCH 2006
National Centre for Classification in Health. The Australian
Classification of Health Interventions (ACHI) 5th edition:
tabular list of Interventions and alphabetic index of
interventions. The University of Sydney, Faculty of Health
Sciences 2006.
Ogbera 2008
Ogbera OA, Osa E, Edo A, Chukwum E. Common
clinical features of diabetic foot ulcers: perspectives from a
developing nation. International Journal of Lower Extremity
Wounds 2008;7(2):93–8.
Pound 2004
Pound N, Chipchase S, Treece K, Game F, Jeffcoate W.
Ulcer-free survival following management of foot ulcers in
diabetes. Diabetic Medicine 2005;22(1):1306–9.
Rafehi 2010
Rafehi H, El-Osta A, Karagiannis TC. Genetic and
epigenetic events in diabetic wound healing. International
Wound Journal 2010;8(1):12–21.
RevMan 2014 [Computer program]
The Nordic Cochrane Centre, The Cochrane Collaboration.
Review Manager (RevMan) Version 5.3. Copenhagen: The
Nordic Cochrane Centre, The Cochrane Collaboration,
2014.
Robbins 2008
Robbins JM, Strauss G, Aron D, Long J, Kuba J, Kaplan
Y. Mortality rates and diabetic foot ulcers: is it time to
communicate mortality risk to patients with diabetic foot
ulceration?. Journal of the American Podiatric Medical
Association 2008;98:489–93.
Schaper 2004
Schaper NC. Diabetic foot ulcer classification system for
research purposes: a progress report on criteria for including
patients in research studies. Diabetes/Metabolism Research
and Reviews 2004;20(Suppl 1):S90-5.
Schaper 2012
Schaper NC. Lessons from Eurodiale. Diabetes/Metabolism
Research and Reviews 2012;28(Suppl 1):21–6.
Schünemann 2011a
Schünemann HJ, Oxman AD, Higgins JPT, Vist GE,
Glasziou P, Guyatt GH. Chapter 11: Presenting results
and ’Summary of findings’ tables. In: Higgins JPT,
Green S (editors). Cochrane Handbook for Systematic
Reviews of Interventions Version 5.1.0 [updated March
2011]. The Cochrane Collaboration, 2011. Available from
www.cochrane-handbook.org.
Schünemann 2011b
Schünemann HJ, Oxman AD, Higgins JPT, Deeks JJ,
Glasziou P, Guyatt GH. Chapter 12: Interpreting results
and drawing conclusions. In: Higgins JPT, Green S
(editors). Cochrane Handbook for Systematic Reviews
of Interventions Version 5.1.0 [updated March 2011].
The Cochrane Collaboration, 2011. Available from
www.cochrane-handbook.org.
Shenoy 2012
Shenoy AM. Guidelines in practice: treatment of painful
diabetic neuropathy. Continuum Lifelong Learning in
Neurology 2012;18(1):192–8.
SIGN 2012
Scottish Intercollegiate Guidelines Network (SIGN). Search
filters. http://www.sign.ac.uk/methodology/filters.html#
random (accessed 10 December 2012).
Singh 2005
Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers
in patients with diabetes. JAMA 2005;293(2):217–28.
Stegenga 2008
Stegenga ME, Van der Crabben SN, Blümer RM, Levi
M, Meijers JC, Serlie MJ, et al. Hyperglycemia enhances
coagulation and reduces neutrophil degranulation, whereas
hyperinsulinemia inhibits fibrinolysis during human
endotoxemia. Blood 2008;112(1):82–9.
Sterne 2011
Sterne JAC, Egger M, Moher D (editors). Chapter 10:
Addressing reporting biases. In: Higgins JPT, Green S
(editors). Cochrane Handbook for Systematic Reviews
of Interventions. Version 5.1.0 (updated March 2011).
The Cochrane Collaboration, 2011. Available from
www.cochrane-handbook.org.
Stratton 2000
Stratton IM, Adler AI, Neil AW, Matthews DR, Manley SE,
Cull CA, et al. Association of glycaemia with macrovascular
and microvascular complications of type 2 diabetes
(UKPDS 35): prospective observational study. BMJ 2000;
321:405–12.
Tesfaye 2012
Tesfaye S, Selvarajah D. Advances in the epidemiology,
pathogenesis and management of diabetic peripheral
neuropathy. Diabetes/Metabolism Research and Reviews
2012;1(1):8–14.
UKPDS 1998
UKPDS. Intensive blood-glucose control with
sulphonylureas or insulin compared with conventional
treatment and risk of complications in patients with type
2 diabetes (UKPDS 33). UK Prospective Diabetes Study
(UKPDS) Group. Lancet 1998;352(9131):837–53.
Wu 2007
Wu SC, Driver VR, Wrobel JS, Armstrong DG. Foot ulcers
in the diabetic patient, prevention and treatment. Journal of
Vascular Health Risk Management 2007;3(1):65–76.
∗ Indicates the major publication for the study
20Intensive versus conventional glycaemic control for treating diabetic foot ulcers (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Idris 2004
Methods Single-centre, prospective, parallel group randomised trial with two arms, and with
clinical assessments performed by assessors blinded to randomisation group. All patients
attending a dedicated multidisciplinary clinic for the management of established foot
ulcers over a 20-week period were systematically screened for inclusion in a randomised,
single-blinded study. The primary endpoints were healing and glycaemic control within
12 weeks. Secondary endpoints included those which were related to the ulcer (change
in ulcer area, amputation), the person (health-related quality of life, survival, pre- and
postprandial glucose concentrations, hypoglycaemia) and the process (withdrawals, costs)
Participants Intended to randomise a total of 50 patients over six months as a pilot for a definitive
randomised controlled trial
• Inclusion criteria were: people with diabetes over the age of 18, with an active
ulcer on or below the malleoli for more than four weeks; cross-sectional area of the
ulcer more than 25 mm2 and less than 2500 mm2; ; able and willing to participate in
the study; able and willing (with or without the help of carer) to undertake frequent
home blood glucose monitoring, and to administer insulin by injection up to four
times daily; HbA1c 7.5% or greater within the preceding two months
• Exclusion criteria were: those with ulcers penetrating to periosteum, joint capsule
or bone, with or without osteomyelitis; those with gangrene; those with chronic renal
failure (serum creatinine > 300 µmol/l in the preceding six months); those with any
illness or disability which would make it inappropriate to consider a multiple injection
regimen; HbA1c < 7.5% within the preceding two months; those with hypoglycaemia
unawareness, or recurrent hypoglycaemic attacks on current therapy, or who believe
that they will have altered hypoglycaemia awareness on the trial preparation; those with
known allergy or sensitivity to any of the preparations to be used; those with
malignancy or unlikely to survive for the duration of the study; those being considered
for re-vascularization; those actively involved in any other study
Interventions Participants were to be randomised to either continue with current hypoglycaemic mea-
sures (adjusted by the usual carers in accordance with perceived clinical need) or to an
intensive effort to achieve tight control
Both groups were to receive equivalent baseline education and be encouraged to perform
regular home blood glucose monitoring.Tight control would be attempted through the
intervention of a diabetes specialist nurse and dietitian (eachwith considerable experience
of attempting close glycaemic control in pregnancy), using one-to-one education linked
to the stepped introduction of basal-bolus insulin therapy, using glargine (Lantus®)
and Novorapid® insulins, adjusted according to the results of home blood glucose
monitoring. The aimwas to achievemean preprandial glucose concentrations of between
5 mmol/l and 7 mmol/l and mean postprandial concentrations of between 7 mmol/l
and 11 mmol/l
Outcomes Out of 200patients attending the clinic, 188were ineligible.Of 12possible recruits, three
who had not had a recentHbA1c were excluded when the result was found to be less than
7.5%. Two were judged incapable of complying with an intensive insulin regimen. Four
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Idris 2004 (Continued)
withheld consent, and one was advised by his community nurse to withhold consent.
One had an ulcer which became clinically infected on the day before his initial visit,
and prior to randomisation. One was successfully recruited and randomised (to the non-
intervention group), and completed the 12 weeks of the study
.
Notes The study was completed and it was established that it was not feasible to undertake such
an intervention in the group of patients managed at that particular specialist clinic. It is
possible that the failure to recruit sufficient numbers was peculiar to the centre, despite
the size of the population being managed, and that other centres might have been more
successful
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Unable to be determined
Allocation concealment (selection bias) Unclear risk Unable to be determined
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Unable to be determined
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unable to be determined
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unable to be determined
Selective reporting (reporting bias) Unclear risk Unable to be determined
Other bias Unclear risk Unable to be determined
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abraira 1992 Foot ulcer healing outcomes or other outcomes relevant to this review were
not investigated in study, authors were unable to provide additional data
for analyses
Abraira 2003 Foot ulcer healing outcomes or other outcomes relevant to this review were
not investigated in study, authors were unable to provide additional data
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for analyses
ACTRN12606000426583 Study prematurely terminated/ was not finished
Althouse 2013 Foot ulcer healing outcomes or other outcomes relevant to this review were
not investigated in study. PAD, lower-extremity revascularization and non-
ulcer-specific lower extremity amputation were documented, but the two
intervention arms did not meet inclusion criteria. All participants were
treated with a target HbA1c of 7.0%
Bayat 2013 Participants were not in intensive versus conventional glycaemic control
arms for comparison
Bloomgarden 1987 Foot ulcer outcomes or other outcomes relevant to this review were not
investigated in study.The study only investigated incidence of foot ulcera-
tion and the impact of ulcer prevention interventions on ulcer incidence
Boaz 2009 Foot ulcer healing outcomes or other outcomes relevant to this review were
not investigated in study. The study assessed the role of prevention and
active checking of foot and leg sores
Calles-Escandon 2010 Foot ulcer healing outcomes or other outcomes relevant to this review were
not investigated in study. The study investigated mortality as an outcome
from intensive control verses conventional control and the authors were
unable to provide additional data for analyses
Chiu 2011 Participants were not in intensive versus conventional glycaemic control
arms for comparison
Christiansen 2009 Foot ulcer healing outcomes or other outcomes relevant to this review were
not investigated in study. Study reported all-cause amputation and ulcer
specific or related amputation data were unable to be provided
Clark 2001 Participants were not randomised to intensive or conventional glycaemic
control arms for comparison
Dormandy 2005 Foot ulcer healing outcomes or other outcomes relevant to this review were
not investigated in study. One secondary outcome was amputation above
the ankle however this was not related to ulcers. Authors were unable to
provide any additional data
Duckworth 2009 Foot ulcer healing outcomes or other outcomes relevant to this review were
not investigated in study. The authors were unable to provide additional
data for analyses. The study investigated the incidence of neuropathy and
neuropathic ulcers with intensive versus conventional control as a preven-
tion measure
23Intensive versus conventional glycaemic control for treating diabetic foot ulcers (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Fresenius 2009 Participants were not in intensive versus conventional glycaemic control
arms for comparison
Gaede 2006 Foot ulcer healing outcomes or other outcomes relevant to this review
were not investigated in study. Amputation results were based on vascular
causes rather than causes related to foot ulceration. Authors were unable
to provide additional clarification
Gaede 2003 Foot ulcer healing outcomes or other outcomes relevant to this review were
not investigated in study and the authors were unable to provide additional
data for analyses
Garber 2002 Foot ulcer healing outcomes or other outcomes relevant to this review were
not investigated in study
Gram 2011 Foot ulcer healing outcomes or other outcomes relevant to this review were
not investigated in study
Griffin 2011 Foot ulcer healing outcomes or other outcomes relevant to this review
were not investigated in study and the authors were unable to provide any
additional data. This was a population-level study with the unit of analyses
not focused on participants or ulcers
Jarnert 2012 Participants were not in intensive versus conventional glycaemic control
arms for comparison
Kawamori 2010 Foot ulcer healing outcomes or other outcomes relevant to this review
were not investigated in study. Only PAD outcomes were reported and
composite outcomes in relation to PAD and other outcomes were reported
Kostev 2012 Non-randomised study design
Leung 2012 Participants were not in intensive versus conventional glycaemic control
arms for comparison
Li 2008 Participants were not in intensive versus conventional glycaemic control
arms for comparison
Litzelman 1993 Participants were not in intensive versus conventional glycaemic control
arms for comparison
Marso 2013 Foot ulcer healing outcomes or other outcomes relevant to this review were
not investigated in this study. The study stated diabetic foot ulcers as a
tertiary outcome but did not report data. Authors were unable to provide
any additional data
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Martinez-Sanchez 2005 Participants were not in intensive versus conventional glycaemic control
arms for comparison
McMurray 2002 Participants were not in intensive versus conventional glycaemic control
arms for comparison
Meigs 2003 Participants were not in intensive versus conventional glycaemic control
arms for comparison
Nathan 2009 Foot ulcer healing outcomes or other outcomes relevant to this review were
not investigated in this study and authors were unable to provide additional
data for analyses. Study reported outcomes on amputation related to severe
neuropathy but not foot ulcers
NCT00850798 Foot ulcer healing outcomes or other outcomes relevant to this review were
not investigated in this study
NCT01421966 Participants were not in intensive versus conventional glycaemic control
arms for comparison
NCT01813305 Participants were not in intensive versus conventional glycaemic control
arms for comparison
Nybo 2011 Foot ulcer healing outcomes or other outcomes relevant to this review were
not investigated in this study and the authors were unable to provide any
additional data
Pedersen 2003 Foot ulcer healing outcomes or other outcomes relevant to this review were
not investigated in this study. Study reported amputations likely related to
vascular causes and the authors were unable to provide any additional data
Rong 2012 Participants were not in intensive versus conventional glycaemic control
arms for comparison
Sullivan 2009 Non-randomised study design
Timlin 2010 Foot ulcer healing outcomes or other outcomes relevant to this review were
not investigated in this study
UK Prospective Diabetes Study (UKPDS) Group 1998 Foot ulcer healing outcomes or other outcomes relevant to this review were
not investigated in this study. Authors stated that outcomes in relation to
foot ulcers were not collected
Vaccaro 2012 Foot ulcer healing outcomes or other outcomes relevant to this review were
not investigated in this study. The study investigatedmajor leg amputations
(above the ankle) and these were not in relation to foot ulcers
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Vadstrup 2009 Foot ulcer healing outcomes or other outcomes in relation to intensive
versus conventional glycaemic control were not reported. Authors could
not provide data on ulcer specific outcomes
Van Olmen 2013 Foot ulcer healing outcomes or other outcomes in relation to intensive
versus conventional glycaemic control were not reported. The main out-
come measure is number of foot ulcers, this study is ongoing currently.
No preliminary results published to date. Proportion of patients with good
glycaemic control used rather than mean HbA1c to randomise patients.
Authors were unable to provide any further information
Williams 2012 Foot ulcer healing outcomes or other outcomes in relation to intensive
versus conventional glycaemic control were not reported. Foot inspections
were reported however this was not in relation to foot ulcers or ulcer healing
outcomes. Authors were unable to provide any further information
Zhang 2011 Localised injection of insulin improved systemic glycaemic control, how-
ever foot ulcer healing outcomes or other outcomes in relation to intensive
versus conventional glycaemic control were not reported. The author was
unable to provide any additional information
Zhang 2013 Foot ulcer healing outcomes or other outcomes in relation to intensive ver-
sus conventional glycaemic control were not reported. Outcomes reported
were not specific to the impact of glycaemic control
Zhenghua 2011 Participants were not in intensive versus conventional glycaemic control
arms for comparison
Please note that when ’foot ulcer outcomes not investigated in study’ was used as a reason for exclusion this was based on whether
studies reported outcomes as deemed appropriate as per the review protocol and/or where data were not available from authors or
where no primary outcomes were investigated at all.
Characteristics of ongoing studies [ordered by study ID]
ACTRN12613000418774
Trial name or title Effects of Galvus (vildagliptin) on markers of inflammation in diabetic foot ulcer: a prospective, randomized,
double-blind, placebo-controlled pilot study
Methods The objective of this trial is to study the effects of vildagliptin therapy on inflammatory markers in subjects
with diabetic foot ulcer. The study plans to prospectively enrol 50 patients with proven diabetic foot ulcer and
randomize them in a 1:1, ratio to vildagliptin +metformin or placebo +metformin. The study expects to show
an improvement (defined as > 20% serum IL-6 reduction between the baseline and 3-month assessment) that
comprise the primary end point in at least 50% of the patients randomized to vildagliptin and metformin
therapy and in < 10% of the patients randomized tometformin and placebo therapy.The proposed sample size
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was calculated to demonstrate a significant improvement in the intervention group compared to the control
group with at least 80% power and a two-sided 5% type 1 error. The authors have quoted a sample size of
44 patients and a 1:1 randomization design to allow for an approximate dropout rate of 10%. Therefore it is
planned that 50 patients will be recruited: this will result in approximately 25 patients in the vildagliptin +
metformin - intervention group and in the placebo + metformin - control group
The data from the study is planned to be pooled and summarized with respect to demographic and baseline
characteristics and efficacy and safety observations. Exploratory analyses will be performed using descriptive
statistics. Data will be presented for the complete intent-to-treat population (all patients having taken at least
one dose of study medication) as well as the per-protocol population (all patients who completed the study
without major protocol deviations)
Participants Inclusion criteria
1) Subjects ≥18 years of age diagnosed with diabetes (type 1 or 2) on diet only or any diabetic medication
regime.
2) Existing diabetes index foot ulcer grade A1 or higher according to the University of Texas Wound Classi-
fication System of Diabetic Foot Ulcers on the day of study inclusion. A foot ulcer will be defined as any full
thickness skin defect existing for at least 14 days. In patients with multiple diabetic foot ulcers the index foot
ulcer is defined as the foot ulcer with the largest wound area at the time of inclusion.
3) A sub-optimal HbA1c ≥ 7.0% documented somewhere in the patient source documents within 12 weeks
prior to study inclusion or on the day of study inclusion
Exclusion criteria
1. Exclusion criteria will comply with local label
2. Clinical infection at the studied ulcer site (bacterial and fungal)
3. Planned surgical intervention for the ulcer
4. Hypersensitivity to either of the study drug components
5. History of lactic acidosis
6. Type 1 diabetes
7. Current HbA1c < 7 or > 9%
8. Current Insulin treatment.
9. Active treatment with GLP-1 or other DPP4i medication
10. Use of thiazolidinediones, statins, anti-inflammatory or anti-platelet agents
11. Clinically significant lower-extremity ischemia (as defined by an ankle/brachial index of < 0.65)
12. Significant medical conditions that would impair wound healing will also be excluded from the study.
These conditions include hepatic, respiratory or cardiac failures, aplastic anemia, scleroderma andmalignancy,
treatment with immunosuppressive agents or steroids, myocardial infarcts, stroke, major surgery within six
months of the study, usage of tobacco
13. Severe non-proliferative or proliferative diabetic retinopathy
14. Active Charcot’s foot as determined by clinical and radiographic examination
15. Ulcer of a non-diabetic pathophysiology (e.g. rheumatoid, radiation-related, and vasculitis-related ulcers,
calciphylaxis or dystrophic calcinosis cutis)
16. Active malignancy other than basal cell carcinoma as well as subjects with cancerous or pre-cancerous
lesions in the ulcer area
17. Renal dysfunction: eGFR < 60 ml/min
18. Chronic inflammation (inflammatory bowel disease, inflammatory or rheumatoid arthritis)
19. Pregnancy, lactation or child-bearing potential
20. Recent venous thromboembolism
21. Inability to comply with study protocol
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Interventions Arm 1: (Intervention group) will be on oral metformin 500 mg to 3000 mg per oral in single or divided
dosages (two or three times a day) plus vildagliptin 50 mg to 100 mg per day also to be administered orally for
12 weeks. The dosages of both medications will be determined based on blood glucose levels with the aim of
achieving average fasting blood glucose of < 7 mmol/l and post-prandial blood glucose of 10 mmol/l or below.
Improved adherence will be enhanced by weekly clinic visit and drug tablet return as well as monitoring blood
glucose control and progress of the diabetic foot ulcer
Arm 2: (Comparator group) will be on given metformin as described above plus placebo comprising lactose
50 mg to 100 mg per day to be taken orally for 12 weeks. The placebo will be identical in appearance to
vildagliptin without the active ingredient
Outcomes Primary outcome: significant (20%) reduction of serum levels of IL-6
IL-6will be quantified using theMultiplex FlowCytomix system (Bendermedsystems). Antibody-coated beads
will be incubated with either patient serum, followed by a biotin-conjugated secondary antibody and finally
streptavidin-PE. The sample will be run on BD caliber. Analysis will be performed using software provided
by the manufacturer
Secondary outcomes:
a) Partial or complete closure of foot ulcer
b) Worsening of the foot ulcer beyond Wagner grade 2
c) Requirement for limb or toe amputation
These will be based on weekly measurement of the ulcer at the start (week 1) and week 12
Starting date 1/08/2013
Contact information Assoc. Professor Usman H. Malabu; FRCPI, FRACP.
School of Medicine and Dentistry
James Cook University & Townsville Hospital
100 Angus Smith Drive
Douglas, Townsville
QLD 4814,Australia
Notes https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364001
*All content above adapted from the published clinical trial record
NCT01472432
Trial name or title DPP IV inhibition facilitates healing of chronic foot ulcers in type 2 diabetes
Methods This study is a randomized versus placebo trial designed to evaluate the clinical and humoral effects of four
months of vildagliptin on healing of chronic ulcers in type 2 diabetes. Both micro and macroangiopathy
strongly contribute to development and delayed healing of diabetic wounds, through an impaired tissue
feeding and response to ischemia. HIF-1α and VEGF, as well as the NO production from iNOS, may
contribute to limitation of hypoxic injury by promoting angiogenesis and wound healing. Experimental and
pathological studies suggest that the incretin hormone glucagon-like peptide-1 (GLP-1) may improve VEGF
generation, and promote pancreatic islet viability through the up-regulation of HIF1α.Therefore, the aim of
this study is to evaluate the effect of the augmentation of GLP-1, by inhibitors of the dipeptidyl peptidase IV
(DPP-4), such as vildagliptin, on HIF-1α, VEGF and iNOS in diabetic chronic ulcers
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Participants Inclusion Criteria
1. Type 2 diabetes
2. Oral hypoglycaemic agents treatment
3. Chronic foot ulcers
4. Adequate blood circulation (perfusion) assessed by a dorsum transcutaneous oxygen test > 30 -mmHg,
ankle brachial index values > 0.7 and < 1.2 with toe pressure > 30 mmHg, or Doppler arterial waveforms
that were triphasic or biphasic at the ankle of the affected leg
5. Written consensus
Exclusion Criteria
1. Active Charcot disease
2. Ulcers resulting from electrical, chemical, or radiation burns
3. Collagen vascular disease
4. Ulcer malignancy
5. Untreated osteomyelitis, or cellulitis
6. Ulcer treatment with normothermic or hyperbaric oxygen therapy
7. Concomitant medications such as corticosteroids, immunosuppressive medications, or chemotherapy
8. Recombinant or autologous growth factor products
9. Skin and dermal substitutes within 30 days of study start
10. Use of any enzymatic debridement treatments
11. Pregnant or nursing mothers
Interventions Experimenta group: vildagliptin
The experimental arm will follow the treatment of placebo group, but received also vildagliptin 50 mg per os
b.i.d. for four months
Placebo group: the dose of other concomitant hypoglycaemic medication will be changed to obtain a similar
profile of metabolic parameters. Additional antidiabetic therapy, including sulphonylurea, metformin, and
insulin, was titrated for optimal glycaemic control for three months. All patients will have diabetes and at
least one full-thickness wound below the ankle for > 3 months. All patients will be examined weekly for
the first four weeks (day 28) then every other week until day 120 or ulcer closure by any means. At each
visit, tracings of the wound margins will be made for computer planimetry to document changes in wound
size, and photographs will be taken for a visual record. All patients will be followed up for regular treatment
at the multidisciplinary diabetic foot clinic, included treatment of infection, debridement, off-loading, and
metabolic control according to high international standards and standard good medical practice
Outcomes Primary Outcome Measures
• Full epithelialization of the wound [ Time Frame: 4 months of treatment with vildagliptin ] [A biopsy
will be performed from the periphery of the ulcer, before and after treatment with vildagliptin, in order to
evaluate the above referred outcome. Optic microscopy is used to evaluate the epithelialization of the wound.
• Capillary density [ Time Frame: 4 months of treatment with vildagliptin].Biopsy is performed from
the periphery of the ulcer, before and after treatment with vildagliptin, in order to evaluate the above
referred outcome. Capillary density will be measured using immunohistochemistry
Secondary Outcome Measures:
• HIF-1α [ Time Frame: 4 months]. The factor will be assessed by immunoblot analysis (commercial
kits). Arbitrary unit of measure will be used.
• VEGF [ Time Frame: 4 months ].The factor will be assessed by immunoblot analysis (commercial kits)
. Arbitrary unit of measure will be used.
• VEGF-R1 (total and phosphorylated form) [ Time Frame: 4 months ]. The receptor will be assessed by
immunoblot analysis (commercial kits). Arbitrary unit of measure will be used.
• VEGF-R2 (total and phosphorylated form) [ Time Frame: 4 months ]. The receptor will be assessed by
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immunoblot analysis (commercial kits). Arbitrary unit of measure will be used.
• iNOS [ Time Frame: 4 months ]. The factor will be assessed by immunoblot analysis (commercial kits)
. Arbitrary unit of measure will be used.
Starting date Unknown, last updated November 15, 2011
Contact information Raffaele Marfella, Assistant Professor, Second University of Naples
Second University of Naples
Naples, Italy, I-80100
Notes https://clinicaltrials.gov/ct2/archive/NCT01472432
*All content above adapted from the published clinical trial record
The information for the ongoing trials listed in the table above was adapted directly from the clinical trial registration source referenced
in the notes section.
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
Table 1. Diabetic foot management guidelines and levels of evidence
Guideline and management recommen-
dations
Level of evidence
(According to Oxford Centre for Evi-
dence-based Medicine - Levels of Evi-
dence (March 2009))
Glycaemic target
National Health and Medical Research
Council (NHMRC): Prevention, iden-
tification and management of foot com-
plications in diabetes mellitus 2011
• Local sharp debridement
• Topical hydrogel dressings
• Pressure reduction
• Offloading
• Removable offloading
• Multidisciplinary care management
• Negative pressure therapy
• Hyperbaric oxygen
• Larval therapy
• Cultured skin equivalents
• Skin grafting
Note: as per NHMRC levels of evidence
Expert opinion
Grade B
Grade B
Grade B
Expert opinion
Grade C
Grade B
Grade B
Grade C
Grade B
Grade D
Not reported
National Clearinghouse Guidelines
2011
• Debridement with multidisciplinary
team
• Off-loading of foot ulcers
• Pressure relieving support surfaces
• Negative pressure wound therapy
• Avoid the use of:
◦ dermal or skin substitutes
◦ electrical stimulation therapy
◦ autologous platelet-rich plasma
gel
◦ regenerative wound matrices
and dalteparin
◦ growth factors
◦ hyperbaric oxygen therapy
Not reported HbA1c < 7%
Level B
National Clearinghouse guidelines 2012
(treatment of neuropathic wounds)
• Assessment by a wound expert Grade C
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Table 1. Diabetic foot management guidelines and levels of evidence (Continued)
National Health Service (NHS): Type 2
diabetes: prevention andmanagement of
foot problems 2004
• Urgent attention within 24 hours
• Multidisciplinary treatment
• Multidisciplinary team comprising a
podiatrist, orthotists, specialised nurse,
diabetologist; with unhindered access to
suites for managing major wounds,
antibiotic administration, urgent
inpatient facilities, community nursing,
microbiology and diabetic services
• Prompt Revascularisation
• Intensive systemic antibiotic therapy
• Appropriate wound dressing
• Close monitoring and regular wound
dressing changes
• Debridement of dead tissue
• Total contact casting
• Hyperbaric oxygen, cultured human
dermis, topical ketanserin or growth
factors
• Foot care reminders
Grade D
Grade D
Grade D
Grade D
Grade C
Grade D
Grade D
Grade B
Grade B
Grade D
Grade B
Not reported
National Health Service (NHS): 2011
National Institute for Health and Care
Excellence (NICE) clinical guideline.
Developed by the Centre for Clinical
Practice at NICE: Diabetic foot prob-
lems: inpatient management of diabetic
foot problems
• Debridement
• Wound dressings
• Offloading
• Antibiotics for infection
• Timing for surgical management.
Not reported Not reported
2012 International Working Group on
Diabetic Foot (IWGDF): Global guide-
line for type 2 diabetes
• Local wound care
• Relief of pressure
• Treatment of infection
• Metabolic control
• Restoration of skin perfusion
Not reported < 8 mmol/l
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Table 1. Diabetic foot management guidelines and levels of evidence (Continued)
Australian diabetic foot Network: Man-
agement of diabetes related foot ulcera-
tion - a clinical update
• Debridement
• Dressing selection
• Pressure offloading
• Management of infection
• Glycaemic control
• Multidisciplinary care
Not reported Not reported
American College of Foot and Ankle sur-
geons 2006 (revision): Diabetic foot dis-
orders - a clinical practice guideline
• Debridement
• Pressure offloading
• Treatment of infection
• Optimise metabolic perturbations
Not reported Not reported
Scottish Intercollegiate Guidelines Net-
work (SIGN) Guidelines 2010
• Referral to a multidisciplinary care
team
• Total contact casts for unilateral
ulcers
• Irremovable walkers
• Negative pressure wound therapy
• Arterial reconstruction for those who
require it
Grade C
Grade B
Grade B
Grade B
Grade B
Not reported
American Diabetes Association Stan-
dards of Medical Care in Diabetes 2012
• Multidisciplinary approach
• Foot ulcers and wound care may
require care by a podiatrist, orthopedic or
vascular surgeon, or rehabilitation
specialist experienced in the management
of individuals with diabetes
Grade B
Not reported
As per position Statement for optimal Con-
trol
Table 2. HbA1c targets recommended by different international guidelines ª
Country Guideline Year Hba1c targets in adults Level of Evidence
(According to Oxford Cen-
tre for Evidence-
based Medicine - Levels of
Evidence (March 2009))
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Table 2. HbA1c targets recommended by different international guidelines ª (Continued)
Australia National
Health and Medical Re-
search Council/Diabetes
Australia
2009 ≤ 7% Grade A
Australian Paediatric En-
docrine Group/ Aus-
tralian Diabetes Society
2011 ≤ 7% Grade D
UK National Institute for
Health and Care Excel-
lence (NICE)
- Managing type 1 DM
diabetes in adults
- Blood glucose lowering
therapy for type 2 DM
2012
2012
≤ 7.5% if increased arterial
risk
≤ 6.5% Between 6.5% and
7.5%
Grade B
Not reported
Not reported
Scottish Intercol-
legiate Guidelines Net-
work (SIGN)
- Type 1 Diabetes
- Type 2 Diabetes
2010
No set figure
< 7%
Not reported
Grade A
USA National Clearinghouse 2012 <7%or individualize to a goal
of < 8%
Grade B
American Diabetes As-
sociation
2012 ≤ 7% or individualise to a
goal:
< 6.5%
< 8%
Grade B
Grade C
Grade B
American Association
of Clinical Endocrinolo-
gists
2011 ≤ 6.5% Grade D
International Diabetes
Federation (IDF)
Inter-
national Diabetes Feder-
ation - Global Guideline
for type 2 Diabetes
2012 < 7.0% U/K
Canada Canadian Diabetes As-
sociation
2008 ≤ 7%
≤ 6.5% (may be considered
to lower risk of nephropathy
further)
Grade C, Level 3
Grade A, Level 1A
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Table 2. HbA1c targets recommended by different international guidelines ª (Continued)
Europe European
Association for the Study
of Diabetes (EASD) and
American Diabetes As-
sociation (ADA)
2012 < 7%or individualise to a goal
of:
6% to 6.5% (patients with
short disease, duration, long
life expectancy, no significant
CVD)
7.5% to8.0% (history of
severe hypoglycaemia, lim-
ited life expectancy, advanced
complications, extensive co-
morbid conditions and those
in
whom the target is difficult to
attain)
Not reported
New Zealand New Zealand Group
Guidelines
2003 ≤ 7% Grade D
ª Adapted from Australian Electronic Therapeutic Guidelines (Electronic Therapeutic Guidelines Australia 2012)
Abbreviations
CVD = cerebrovascular disease
DM = diabetes mellitus
U/K = unknown
Table 3. Commonly used medications in diabetes mellitus (type 1 and type 2) for the management of hyperglycaemia.
Class/Drug Expected decrease in HbA1c
ORAL ANTIDIABETIC THERAPY
Metformin 1% to 2%
Sulfonylureas
• glibenclamide
• gliclazide
• glimepiride
• glipizide
1% to 2%
DPP-4-inhibitors
• sitagliptin
• vildagliptin,
• saxagliptin
• linagliptin
• anagliptin
• alogliptin
0.5% to 0.8%
Acarbose 0.5% to 0.8%
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Table 3. Commonly used medications in diabetes mellitus (type 1 and type 2) for the management of hyperglycaemia.
(Continued)
Thiazolidinedione (glitazones)
• pioglitazone
• rosglitazone
0.5% to 1.4%
PARENTERAL THERAPY
GLP-analogues
• exenatide
• liraglutide
• lixisenatide
0.5% to 1.0%
Insulin 1.5% to 3.5%
Insulin Generic name
Very-short-acting (rapid) Aspart
Glulisine
Lispro
Short-acting Neutral
Intermediate-acting Isophane (protamine suspension)
Long-acting Determir
Glargine
Biphasic Neutral/isophane
Lispro/lispro protamine
Aspart/aspart protamine
Methods of insulin delivery
• Syringe
• Pen injector
• Pump/continuous subcutaneous insulin infusion
Table 4. Alternative treatments for lowering blood glucose in people with diabetic foot ulcers
Nature of intervention
Exercise Psychological and behavioural Dietary
Any exercise intervention that has the pri-
mary aim of improving glycaemic control
in people with diabetes, where the impact
of the intervention on glycaemic control
and changes in an active foot ulcer has been
Any psychological or behavioural interven-
tion that has the primary aim of improving
glycaemic control in people with diabetes,
where the impact of the intervention on
glycaemic control and the resultant changes
Any dietary or nutritional intervention that
has the primary aim of improving gly-
caemic control in people with diabetes,
where the changes in glycaemic control
have been correlated with changes in active
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Table 4. Alternative treatments for lowering blood glucose in people with diabetic foot ulcers (Continued)
documented in a foot ulcer has been documented foot ulcer outcome
Examples
Exercise programmes of any intensity and
duration that had the primary aim of im-
provement in glycaemic control
Frequent checking of blood glucose levels,
interventions aimed at good pharmaceu-
tical practice (i.e. improving compliance
with medication)
Healthy eating programmes, dietary or nu-
tritional supplements
A P P E N D I C E S
Appendix 1. Glossary of Terms
Diabetes: a disease caused by reduced production of the hormone insulin, or a reduced response of the liver, muscle, and fat cells to
insulin. This affects the body’s ability to use and regulate sugars effectively.
Diabetic Peripheral Neuropathy (DPN): damage to the peripheral nerves that is characterised by numbness, tingling, pain, or
sometimes muscle weakness, particularly in the extremities.
Peripheral Arterial Disease (PAD): narrowing or obstruction of the arteries supplying the legs that is characterised by intermittent
claudication (numbness, tingling and pain in the legs that occurs on walking, but is relieved by a short rest).
Hyperglycaemia: excessive glucose (sugar) in the blood.
HbA1c (glycated haemoglobin): a commonly used laboratory measurement that measures average blood glucose levels over the
previous two to three months.
Microvascular: small blood vessels.
Macrovascular: large blood vessel.
Nephropathy: disorder of the kidney that includes inflammatory, degenerative and sclerotic (scar forming) conditions.
Retinopathy: disease of the small retinal blood vessels in the eye.
Growth factors: chemical messengers that induce cell growth.
Glycation: binding of a sugar molecule to an amino-acid. In hyperglycaemia, sugar molecules become attached to cell surface proteins
throughout the body; this sugar coating leads to small blood vessel damage in nerves, kidney, and the retina.
Polyol pathway: metabolic pathway involved in breakdown of excess glucose.
Advanced Glycation End products (AGEs): proteins that have been non-enzymatically modified by the addition of sugar residues.
Reactive Oxygen Species (ROS):molecules and ions of oxygen that have an unpaired electron, which makes them extremely reactive.
Many cellular structures are susceptible to damage by reactive oxygen species.
DAG-protein kinase C pathway: metabolic pathway involved in diabetes-related complications.
Hexosamine pathway: metabolic pathway involved in diabetes-related complications.
Mitochondria: involved in respiration and adenosine tri-phosphate (ATP; energy) production.
Endothelial: cells lining the heart, blood vessels and lymph vessels.
Angiogenesis: process of forming new blood vessels.
NF-κB: transcription factor involved in activation of genes involved in the inflammatory response.
Ulcer grading scale: an ulcer grading system implies any system where the dimensional change in an ulcer has been documented - e.g.
the University of Texas Wound Classification System (UTWS), PEDIS system or another.
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Appendix 2. Search strategies
Cochrane Wounds Specialised Register
#1 (((blood glucose or (glycaemic or glycemic) next control) or “intensive glucose control” or (hypoglycaemi* or hypoglycemi*) next
(agent* or drug*))) AND (INREGISTER)
#2 (((oral next (hypoglycaemi* or hypoglycemi*)) or (“fasting glucose” or “glucose target” or anti-diabetes medication* or diabetes
medication* or insulin* or sulphonyureas or metformin or thiazolidinedione* or DPP-4 inhibitor* or glitinide or glucosidase inhibitor*
or biguinide or “GLP-1 agonist” or acarbose or incretin next enhancer* or incretin next mimetic* or HbA1c))) AND (INREGISTER)
#3 #1 OR #2
#4 (((diabet* near3 ulcer*) or (foot near3 ulcer*) or (feet near3 ulcer*) or (foot near3 defect*) or (“foot gangrene” or amputat*))) AND
(INREGISTER)
#5 #3 AND #4
Ovid MEDLINE
1 exp Blood Glucose/
2 exp Hypoglycemic Agents/
3 exp Hyperglycemia/
4 exp Hypoglycemia/
5 exp Insulin/
6 exp Metformin/
7 exp Thiazolidinediones/
8 exp alpha-Glucosidases/
9 exp Glucagon-Like Peptide 1/
10 exp Acarbose/
11 blood glucose.tw.
12 (((glycaemic or glycemic) adj control) or “intensive glucose control”).tw.
13 ((hypoglycaemi* or hypoglycemi*) adj (agent* or drug*)).tw.
14 (oral adj (hypoglycaemi* or hypoglycemi*)).tw.
15 (fasting glucose or glucose target).tw.
16 (anti-diabetes medication* or diabetes medication* or insulin* or sulphonylureas or metformin or thiazolidinedione* or DPP-4
inhibitor* or glitinide or glucosidase inhibitor* or biguanide or GLP-1 agonist or acarbose or incretin enhancer* or incretin mimetic*
or HbA1c).tw.
17 or/1-16
18 exp Foot Ulcer/
19 exp Diabetic Foot/
20 (diabet* adj3 ulcer*).tw.
21 (diabet* adj3 (foot or feet)).tw.
22 (diabet* adj3 wound*).tw.
23 (diabet* adj3 defect*).tw.
24 (foot gangrene or amputat*).tw.
25 or/18-24
26 17 and 25
27 randomized controlled trial.pt.
28 controlled clinical trial.pt.
29 randomi?ed.ab.
30 placebo.ab.
31 clinical trials as topic.sh.
32 randomly.ab.
33 trial.ti.
34 or/27-33
35 exp animals/ not humans.sh.
36 34 not 35
37 26 and 36
Ovid EMBASE
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1 exp glucose blood level/
2 exp antidiabetic agent/
3 exp hyperglycemia/
4 exp hypoglycemia/
5 exp insulin/
6 exp metformin/
7 exp 2,4 thiazolidinedione derivative/
8 exp alpha glucosidase/
9 exp glucagon like peptide 1/
10 exp acarbose/
11 blood glucose.tw.
12 (((glycaemic or glycemic) adj control) or “intensive glucose control”).tw.
13 ((hypoglycaemi* or hypoglycemi*) adj (agent* or drug*)).tw.
14 (oral adj (hypoglycaemi* or hypoglycemi*)).tw.
15 (fasting glucose or glucose target).tw.
16 (anti-diabetes medication* or diabetes medication* or insulin* or sulphonylureas or metformin or thiazolidinedione* or DPP-4
inhibitor* or glitinide or glucosidase inhibitor* or biguanide or GLP-1 agonist or acarbose or incretin enhancer* or incretin mimetic*
or HbA1c).tw.
17 or/1-16
18 exp foot ulcer/
19 exp diabetic foot/
20 (diabet* adj3 ulcer*).tw.
21 (diabet* adj3 (foot or feet)).tw.
22 (diabet* adj3 wound*).tw.
23 (diabet* adj3 defect*).tw.
24 (foot gangrene or amputat*).tw.
25 or/18-24
26 17 and 25
27 Randomized controlled trials/
28 Single-Blind Method/
29 Double-Blind Method/
30 Crossover Procedure/
31 (random$ or factorial$ or crossover$ or cross over$ or cross-over$ or placebo$ or assign$ or allocat$ or volunteer$).ti,ab.
32 (doubl$ adj blind$).ti,ab.
33 (singl$ adj blind$).ti,ab.
34 or/27-33
35 exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/
36 human/ or human cell/
37 and/35-36
38 35 not 37
39 34 not 38
40 26 and 39
EBSCO CINAHL
S39 S26 AND S38
S38 S27 or S28 or S29 or S30 or S31 or S32 or S33 or S34 or S35 or S36 or S37
S37 MH “Quantitative Studies”
S36 TI placebo* or AB placebo*
S35 MH “Placebos”
S34 TI random* allocat* or AB random* allocat*
S33 MH “Random Assignment”
S32 TI randomi?ed control* trial* or AB randomi?ed control* trial*
S31 AB ( singl* or doubl* or trebl* or tripl* ) and AB ( blind* or mask* )
S30 TI ( singl* or doubl* or trebl* or tripl* ) and TI ( blind* or mask* )
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S29 TI clinic* N1 trial* or AB clinic* N1 trial*
S28 PT Clinical trial
S27 MH “Clinical Trials+”
S26 S17 AND S25
S25 S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24
S24 TI ( foot gangrene or amputat* ) OR AB ( foot gangrene or amputat* )
S23 TI diabet* N3 defect* or AB diabet* N3 defect*
S22 TI diabet* N3 wound* or AB diabet* N3 wound*
S21 TI diabet* N3 foot OR diabet* N3 feet* or AB diabet* N3 foot OR diabet* N3 feet
S20 TI diabet* N3 ulcer* or AB diabet* N3 ulcer*
S19 (MH “Foot Ulcer+”)
S18 (MH “Diabetic Foot”)
S17 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16
S16 AB anti-diabetes medication* or diabetes medication* or insulin* or sulphonyureas or metformin or thiazolidinedione* or DPP-4
inhibitor* or glitinide or glucosidase inhibitor* or biguinide or GLP-1 agonist or acarbose or incretin enhancer* or incretin mimetic*
or HbA1c
S15 TI anti-diabetes medication* or diabetes medication* or insulin* or sulphonyureas or metformin or thiazolidinedione* or DPP-4
inhibitor* or glitinide or glucosidase inhibitor* or biguinide or GLP-1 agonist or acarbose or incretin enhancer* or incretin mimetic*
or HbA1c
S14 TI ( fasting glucose or glucose target ) OR AB ( fasting glucose or glucose target )
S13 TI ( oral hypoglycaemi* or oral hypoglycemi* ) OR AB ( oral hypoglycaemi* or oral hypoglycemi* )
S12 TI ( hypoglycaemi* agent* or hypoglycemi* agent* or hypoglycaemi* drug* or hypoglycemi* drug* ) OR AB ( hypoglycaemi*
agent* or hypoglycemi* agent* or hypoglycaemi* drug* or hypoglycemi* drug* )
S11 TI ( glycaemic control or glycemic control or “intensive glucose control” ) OR AB ( glycaemic control or glycemic control or
“intensive glucose control” )
S10 TI blood glucose OR AB blood glucose
S9 (MH “Acarbose”)
S8 (MH “Glucagon-Like Peptide 1”)
S7 (MH “Thiazolidinediones+”)
S6 (MH “Metformin”)
S5 (MH “Insulin+”)
S4 (MH “Hypoglycemia+”)
S3 (MH “Hyperglycemia+”)
S2 (MH “Hypoglycemic Agents+”)
S1 (MH “Blood Glucose”)
Elsevier SCOPUS
1. (TITLE-ABS-KEY(blood PRE/3 glucose)ORTITLE-ABS-KEY(hypoglyc*mic PRE/3 agent*ORhyperglyc*miaORhypoglyc*mia)
OR TITLE-ABS-KEY(insulin* OR metformin OR thiazolidinedione*) OR TITLE-ABS-KEY({alpha-glucosidases} OR {glucagon-
like peptide 1}) OR TITLE-ABS-KEY(acarbose OR {blood glucose}) OR TITLE-ABS-KEY(glyc*mic W/3 control OR {intensive
glucose control}) OR TITLE-ABS-KEY(agent* W/3 hypoglycaemi* OR hypoglycemi*) OR TITLE-ABS-KEY(drug* W/3 hypogly-
caemi* OR hypoglycemi*) OR TITLE-ABS-KEY(oral W/3 hypoglycaemi* OR hypoglycemi*) OR TITLE-ABS-KEY(“fasting glu-
cose” OR “glucose target”) OR TITLE-ABS-KEY({anti-diabetes} W/3 medication* OR diabetes W/3 medication*) OR TITLE-ABS-
KEY(sulphonylureas OR sulfonylureas OR “dpp-4 inhibitor*”) OR TITLE-ABS-KEY(glitinide OR glucosidase W/3 inhibitor*) OR
TITLE-ABS-KEY(biguanide OR {GLP-1 agonist} OR incretin W/3 enhancer*) OR TITLE-ABS-KEY(incretin W/3 mimetic* OR
hba1c))
2. Searched within results from above search for each of the following terms (combined with Boolean “AND” operator):-
Foot w/3 ulcer
Diabet* w/3 foot or feet
Diabet* w/3 ulcer*
Diabet* w/3 wound*
Diabet* w/3 defect*
foot gangrene
amputat*
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ISI Web of Knowledge Web of Science
1. Topic=(blood near/3 glucose) OR Topic=(hypoglyc*mic near/3 agent* or hyperglyc*mia or hypoglyc*mia) OR Topic=(Insulin*
or Metformin or Thiazolidinedione*) OR Topic=(alpha-glucosidases or “glucagon-like peptide 1”) OR Topic=(Acarbose or “blood
glucose”) OR Topic=(Glyc*mic near/3 control or “intensive glucose control”) OR Topic=(Agent* near/3 hypoglycaemi* or hypo-
glycemi*) OR Topic=(Drug* near/3 hypoglycaemi* or hypoglycemi*) OR Topic=(Oral near/3 hypoglycaemi* or hypoglycemi*) OR
Topic=(“fasting glucose” or “glucose target”) OR Topic=(anti-diabetes near/3 medication* or diabetes near/3 medication*) OR Topic=
(Sul*onylureas or “DPP-4 inhibitor*”) ORTopic=(glitinide or glucosidase near/3 inhibitor*) ORTopic=(Biguanide or “GLP-1 agonist”
or incretin near/3 enhancer*) OR Topic=(Incretin near/3 mimetic* or HbA1c)
2. Results from above search results were combined with each of the following terms:-
Foot near/3 ulcer*
Diabet* near/3 foot or feet
Diabet* near/3 ulcer*
Diabet* near/3 wound*
Diabet* near/3 defect*
“foot gangrene”
amputat*
3. Duplicates were removed and remaining references were searched for the following terms as [as field contains]:-
Randomized
Randomised
Controlled clinical trial
Placebo
Drug therapy
Randomly
Trial
Groups
BioMed Central
1. Randomized or randomised or “controlled clinical trial” or placebo or drug therapy or randomly or trial or groups (All words) in All
fields (full text)
2. Searched within #1 for:
“Foot and ulcer*” or (diabet* and foot or diabet* and feet) or “Diabet* and ulcer*” or “Diabet* and wound*” or “Diabet* and defect*”
or “foot and gangrene” or amputat*)
3. Searched within #2 for each of the following terms in All fields (full text):
“blood glucose” or “Hypoglyc*mic agent*” or hyperglyc*mia or hypoglyc*mia
OR
Insulin* or Metformin or Thiazolidinedione* or “alpha-glucosidases” or “alpha glucosidases”
OR
“glucagon-like peptide 1” or “glucagon like peptide 1” or Acarbose or “Glyc*mic control”
OR
“intensive glucose control” or “Hypoglyycaemi* agent” or “hypoglycemi* agent” or “hypoglycaemi* drug*” or “hypoglycemi* drug*”
OR
“Oral hypoglycaemi*” or “oral hypoglycemi*” or “fasting glucose” or “glucose target” or “anti-diabetes medication*” or “diabetes
medication*” or Sul*onylureas or “DPP-4 inhibitor*”
OR
glitinide or “glucosidase inhibitor*” or Biguanide or “GLP-1 agonist” or “incretin enhancer*” or “Incretin mimetic*” or “HbA1c”
LILACS
1. ( blood glucose ) or “BLOOD GLUCOSE” or “BLOOD GLUCOSE/” or “BLOOD GLUCOSE/AN” or “BLOOD GLU-
COSE/BI” or “BLOOD GLUCOSE/BL” or “BLOOD GLUCOSE/CH” or “BLOOD GLUCOSE/DE” or “BLOOD GLUCOSE/
DU” or “BLOOD GLUCOSE/GE” or “BLOOD GLUCOSE/IM” or “BLOOD GLUCOSE/ME” or “BLOOD GLUCOSE/MT”
or “BLOOD GLUCOSE/PH” or “BLOOD GLUCOSE/RE” or “BLOOD GLUCOSE/ST” [Subject descriptor] and “HYPO-
GLYCEMIC AGENTS” [Subject descriptor] and “HYPERGLYCEMIA” or “postprandial HYPERGLYCEMIA” [Subject descriptor]
2. “HYPOGLYCEMIA” [Subject descriptor] or “INSULIN” [Subject descriptor] or “METFORMIN” [Subject descriptor]
3. “THIAZOLIDINEDIONES” [Subject descriptor] or “ALPHA-GLUCOSIDASES” [Subject descriptor] or “GLUCAGON-LIKE
PEPTIDE 1” or “GLUCAGON-LIKE PEPTIDEs” [Subject descriptor]
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4. acarbose [Subject descriptor]
5. “BLOOD GLUCOSE” or “BLOOD GLUCOSE/” [Words] or “GLYCEMICCONTROL” or “GLYCEMICSELF-CONTROL”
[Words]
6. “HYPOGLYCEMIC AGENTS” or “HYPOGLYCEMIC AGENTS/” or “HYPOGLYCEMIC AGENTS/AD” or “HYPO-
GLYCEMIC AGENTS/AE” or “HYPOGLYCEMIC AGENTS/AN” or “HYPOGLYCEMIC AGENTS/BL” or “HYPOGLYCEMIC
AGENTS/CH” or “HYPOGLYCEMIC AGENTS/CL” or “HYPOGLYCEMIC AGENTS/CT” or “HYPOGLYCEMIC AGENTS/
DU” or “HYPOGLYCEMIC AGENTS/EC” or “HYPOGLYCEMIC AGENTS/IM” or “HYPOGLYCEMIC AGENTS/IP” or
“HYPOGLYCEMIC AGENTS/ME” or “HYPOGLYCEMIC AGENTS/PD” or “HYPOGLYCEMIC AGENTS/PK” or “HYPO-
GLYCEMICAGENTS/PO” or “HYPOGLYCEMIC AGENTS/SD” or “HYPOGLYCEMIC AGENTS/TO” or “HYPOGLYCEMIC
AGENTS/TU” or “HYPOGLYCEMIC/HYPOTRIGLYCERIDEMIC” or “HYPOGLYCEMICAGENTS” [Words]
7. No words found in the index for: oral hypoglyc[a]emi*
8. No words found in the index for: glucose target
9. “FASTINGGLUCOSE” [Words]
10. “ANTI-DIABETES” or “ANTI-DIABETIC” or “ANTI-DIABETICA” or “ANTI-DIABETICAS” or “ANTI-DIABETICO” or
“ANTI-DIABETICOS” or “ANTI-DIABETICS” [Words] or “INSULIN” [Words] or “SULPHONYLUREA” or “SULPHONY-
LUREA-BASED” or “SULPHONYLUREAS” [Words]
No words found in the index for: diabetes next medication*
11. “SULFONYLUREAS” or “SULFONYLUREA” or “SULFONYLUREA COMPOUNDS” or “SULFONYLUREA COM-
POUNDS/” or “SULFONYLUREA COMPOUNDS/AD” or “SULFONYLUREA COMPOUNDS/AE” or “SULFONYLUREA
COMPOUNDS/BL” or “SULFONYLUREA COMPOUNDS/CL” or “SULFONYLUREA COMPOUNDS/CT” or “SULFONY-
LUREACOMPOUNDS/PD” or “SULFONYLUREACOMPOUNDS/PK” or “SULFONYLUREACOMPOUNDS/PO” or “SUL-
FONYLUREA COMPOUNDS/TO” or “SULFONYLUREA COMPOUNDS/TU” or “SULFONYLUREAS” [Words] or “MET-
FORMIN” or “METFORMIN’S” or “METFORMIN-INDUCED” or “METFORMIN-TREATED” or “METFORMIN/” or
“METFORMIN/AD” or “METFORMIN/AE” or “METFORMIN/AN” or “METFORMIN/CH” or “METFORMIN/CT” or
“METFORMIN/DU” or “METFORMIN/EC” or “METFORMIN/GLIMEPIRIDE” or “METFORMIN/ME” or “METFORMIN/
PD” or “METFORMIN/PK” or “METFORMIN/TO” or “METFORMIN/TU” or “METFORMINA” or “METFORMINA-
GLIBEN-CLAMIDA”or “METFORMINA.” or “METFORMINA/” or “METFORMINA/AD”or “METFORMINA/AE”or “MET-
FORMINA/AN” or “METFORMINA/CH” or “METFORMINA/CT” or “METFORMINA/DU” or “METFORMINA/EC” or
“METFORMINA/GLIMEPIRIDA” or “METFORMINA/ME” or “METFORMINA/PD” or “METFORMINA/PK” or “MET-
FORMINA/TO” or “METFORMINA/TU” or “METFORMINADE” or “METFORMINAHCL” or “METFORMINAND” or
“METFORMINAREVISAO” or “METFORMINCONCLUSIONS” or “METFORMINE” or “METFORMINGROUP” or “MET-
FORMINHCL” or “METFORMYN” [Words] or “THIAZOLIDINEDIONAS” or “THIAZOLIDINEDIONE” or “THIAZO-
LIDINEDIONES” or “THIAZOLIDINEDIONES/” or “THIAZOLIDINEDIONES/AD” or “THIAZOLIDINEDIONES/AE”
or “THIAZOLIDINEDIONES/AG” or “THIAZOLIDINEDIONES/CH” or “THIAZOLIDINEDIONES/EC” or “THIAZO-
LIDINEDIONES/ME” or “THIAZOLIDINEDIONES/PD” or “THIAZOLIDINEDIONES/TU” or “THIAZOLIDINONE” or
“THIAZOLINEDIONES” [Words]
12. “BIGUANIDA” or “BIGUANIDAS” or “BIGUANIDAS/” or “BIGUANIDAS/AD” or “BIGUANIDAS/AE” or “BIGUANIDAS/
AN” or “BIGUANIDAS/CH” or “BIGUANIDAS/CT” or “BIGUANIDAS/DU” or “BIGUANIDAS/ME” or “BIGUANIDAS/
PD” or “BIGUANIDAS/PK” or “BIGUANIDAS/ST” or “BIGUANIDAS/TU” or “BIGUANIDE” or “BIGUANIDE-BASED”
or “BIGUANIDE-DERIVATIVE” or “BIGUANIDES” or “BIGUANIDES/” or “BIGUANIDES/AD” or “BIGUANIDES/AE”
or “BIGUANIDES/AN” or “BIGUANIDES/CH” or “BIGUANIDES/CT” or “BIGUANIDES/DU” or “BIGUANIDES/ME”
or “BIGUANIDES/PD” or “BIGUANIDES/PK” or “BIGUANIDES/ST” or “BIGUANIDES/TU” or “BIGUANIDICO” or
“BIGUANIDIL” or “BIGUANIDINS” or “BIGUANIDOS” [Words] or “ACARBOSA” or “ACARBOSA/AD” or “ACARBOSA/AE”
or “ACARBOSA/CT” or “ACARBOSA/ME” or “ACARBOSA/PD” or “ACARBOSA/TU” or “ACARBOSE” or “ACARBOSE-IN-
DUCED” or “ACARBOSE-TREATED” or “ACARBOSE/AD” or “ACARBOSE/AE” or “ACARBOSE/CT” or “ACARBOSE/ME” or
“ACARBOSE/PD” or “ACARBOSE/TU” [Words] or “INCRETIN-MIMETICS” or “INCRETINA-MIMETICOS” or “INCRET-
INMIMETICS” or “INCRETINOMIMETICAS” or “INCRETINOMIMETICOS” [Words]
No words found in the index for: glitinide; glucosidase inhibitor*; incretin next enhancer*
13. “GLP-1” or “GLP-1.” or “GLP1” or “GLP1:” [Words] and “AGONIST” or “AGONIST’S” or “AGONIST--IN” or “AGONIST-
ANTAGONIST” or “AGONIST-BINDING” or “AGONIST-HOLD-RELAX” or “AGONIST-INDUCED” or “AGONIST-LIKE”
or “AGONIST-MEDIATED” or “AGONIST-RECEPTOR” or “AGONIST-SPECIFIC” or “AGONIST-TO-ANTAGONIST” or
“AGONIST-UINDUCED” or “AGONIST/ANTAGONIST” or “AGONIST/ANTAGONISTAS” or “AGONIST/CHLORIDE”
or “AGONISTA” or “AGONISTAS” [Words]
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14. “HBA1:C287C” OR “HBA1:C46G” OR “HBA1C”OR “HBA1C>9.5” OR “HBA1C-PESO”OR “HBA1C10” OR “HBA1C12”
OR “HBA1CLEVELS” OR “HBA1CMEASUREMENT” OR “HBA1CMETODOS” [Words]
The results of searches #1-#14 were combined with the “OR” Boolean operator and duplicates were removed.
The results were combined with the “foot ulcer” concept terms, as below. Terms #15-#23 were individually searched within the results
for #1-#14.
15. Foot [and] ulcer
16. Diabetic foot
17. Diabet* [and] ulcer*
18. Diabet* [and] foot
19. Diabet* [and] feet
20. Diabet* [and] wound*
21. Diabet* [and] defect*
22. Foot gangrene
23. Amputat*
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We changed the term diabetes foot ulcer to diabetic foot ulcer to be consistent with other reviews investigating various modalities on
foot ulcer healing in people with diabetes. Also please note that Incidence of amputation cited as a primary outcome measure in this
review related to amputation as a result of foot ulceration and not “all cause” amputation.
N O T E S
The review authors agreed to change the title to ’Intensive versus conventional glycaemic control for treating diabetic foot ulcers’,
because of the wider use of the term ’intensive glycaemic control’ over ’strict glycaemic control’ within the literature, and also because
of external reviewers’ comments.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Diabetes Mellitus, Type 1 [∗complications]; Diabetes Mellitus, Type 2 [∗complications]; Diabetic Foot [etiology; ∗therapy]; Hyper-
glycemia [complications; ∗therapy]
MeSH check words
Humans
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